



MINISTERIO
DE ECONOMIA Y
COMPETITIVIDAD

DIRECCIÓN GENERAL DE INVESTIGACIÓN Y
GESTIÓN DEL PLAN NACIONAL DE I+D+i

SUBDIRECCIÓN GENERAL DE FORMACIÓN E
INCORPORACIÓN DE INVESTIGADORES

Curriculum vitae Standardized form

Name: VICENTE ANDRÉS GARCÍA, PhD

Spanish National ID: 43398205B

Date: 20/10/2016

During the evaluation process the applicant could be required to expand and justify the information here contained.

PERSONAL DATA

- Last name: Andrés García
- First name: Vicente
- Date and place of birth: June 3, 1962. Valencia, Spain
- Marital status: Married (2 children)

CURRENT PROFESSIONAL POSITION

- Institution: Institute of Health Carlos III (Instituto de Salud Carlos III)
Faculty, School or Institute: Spanish National Center for Cardiovascular Research (Centro Nacional de Investigaciones Cardiovasculares Carlos III, CNIC. Awarded "Centro de Excelencia Severo Ochoa" (2012-2015 and 2016-2019)
- Vascular pathophysiology Area
- Address: C/ Melchor Fernández Almagro 3, 28029 Madrid, Spain
- Telephone: +34 91 453 12 00 ext.1502
- Fax: +34 91 453 12 65
- E-mail: vandres@cnic.es
- Professional status: Full Professor (since 1/9/2009)
Director Department of Basic Research (since 1/2/2015)

CURRENT RESEARCH INTERESTS

Field of study (UNESCO code): 241500

- To elucidate molecular and genetic mechanisms that control the initiation and progression of vascular obstructive lesions in the setting of native atherosclerosis and post-angioplasty restenosis, with special emphasis on the regulation of cellular proliferation and gene transcription.
- To investigate the role of lamin A/C in the regulation of gene expression and signal transduction in health and disease
- To investigate molecular and cellular mechanisms underlying physiological ageing as well as Hutchinson-Gilford progeria syndrome (HGPS), a premature ageing disorder caused by the lamin A mutant progerin which is characterized by excessive cardiovascular disease and premature death.

EDUCATION

- | | |
|------|---|
| 1986 | Bachelor's Degree, Biology, University of Barcelona |
| 1990 | PhD, Biological Sciences, University of Barcelona (Supervisor: Dr. Roser Cussó) |

ACADEMIC APPOINTMENTS

- | | |
|-----------|---|
| 1986-1987 | Teaching Assistant, Department of Biochemistry, School of Medicine, University of Barcelona, Spain |
| 1986-1990 | Graduate Student, Department of Biochemistry, School of Medicine, University of Barcelona, Spain |
| 1991-1994 | Postdoctoral Fellow, Department of Cardiology, and Department of Pediatrics, Harvard Medical School, Children's Hospital and Harvard University, Boston, US |
| 1994-1995 | Postdoctoral Fellow, Division of Cardiovascular Research and Department of Biomedical Research, St. Elizabeth's Medical Center, Tufts University, Boston, US |
| 1994-1996 | Assistant Investigator, Division of Cardiovascular Research and Department of Biomedical Research, St. Elizabeth's Medical Center, Tufts University, Boston, US |

1995-2000	Assistant Professor, Department of Medicine, Tufts University, Boston, US
1996-1999	Investigator, Division of Cardiovascular Research and Department of Biomedical Research, St. Elizabeth's Medical Center, Tufts University, Boston, US
1997-2003	Tenured Scientist, Biomedical Institute of Valencia (IBV), Spanish Council for Scientific Research (CSIC), Spain
2003-2005	Research Scientist, Biomedical Institute of Valencia (IBV), Spanish Council for Scientific Research (CSIC), Spain
2003-2009	Head of Department of Molecular and Cellular Pathology and Therapy, Biomedical Institute of Valencia (IBV), Spanish Council for Scientific Research (CSIC), Spain
2005-2009	Full Professor, Biomedical Institute of Valencia (IBV), Spanish Council for Scientific Research (CSIC), Spain. On voluntary leave of absence since August 30, 2009
2009-present	Full Professor, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)
2015-present	Director Department of Basic Research, CNIC
2015- 2016	Professor "ad honorem", Department of Biochemistry, Universidad Autónoma de Madrid.

TEACHING

Participation in Masters and Doctoral Courses for PhD and undergraduate students organized by Spanish Universities

LANGUAGES (N = NORMAL, G = GOOD, P = PERFECTLY)

<i>Language</i>	<i>Speaking</i>	<i>Reading</i>	<i>Writing</i>
Spanish	P	P	P
English	G	P	P
French	N	G	N

FELLOWSHIPS

1983-1985	Fellowship, Spanish National Institute for Student's Guidance and Promotion (Instituto Nacional de Ayuda y Promoción del Estudiante), Resident Student
1987-1990	FPI PhD Fellowship, Spanish Ministry of Science and Education
1991-1992	FPI Postdoctoral Fellowship, Spanish Ministry of Science and Education
1993-1994	Postdoctoral Fellowship, American Heart Association, Massachusetts Affiliate

REMARKS IN SCIENTIFIC JOURNALS

2010	Spotlight: Vicente Andrés, PhD. Circulation 121:f94-f96 (special section European Perspectives; http://circ.ahajournals.org/content/121/16/f91.full.pdf+html)
2010	Thought-Provoking Quotes 2010. Circulation 122:f148-f149 (special section European Perspectives; http://circ.ahajournals.org/content/122/25/f145.full.pdf+html)

- 2011 Funding: Doctor Léon Dumont Prize. **Circulation** 124:f70-f71 (special section European Perspectives; <http://circ.ahajournals.org/content/124/12/f67.full.pdf+html>)

HONORS AND AWARDS

- 1996 Finalist, Irvine H. Young Investigator Award (Atherosclerosis), American Heart Association
- 1997 Finalist, New England Cardiovascular Research Award, Astra Merck
- 2001 Best Communication Award, XXXVII National Congress of the Spanish Society of Cardiology, Spanish Heart Society
- 2002 Second Prize, Research Award "Ageing and Quality of Life", Pfizer Foundation
- 2006 Novartis Research Grant 2006, Spanish Society of Cardiology
- 2010 Winner, Dr. León Dumont Prize 2010, Belgian Society of Cardiology
- 2010 Joint Runner Up Prize in the Young Investigator Award Poster Competition, Heart Failure Winter Research Meeting on "Translational Heart Failure Research", European Society of Cardiology, Les Diablerets, Switzerland (presented by J. J. Fuster)
- 2011 Biology of the Cell Poster Prize, The Biochemical Society Focused Meeting on "Nuclear Envelope Disease and Chromatin Organization", Cambridge, UK (presented by J. M^a González) (co-authors: J.M. González, V. Rocha-Perugini, F.G. Osorio, C. López-Otín, F. Sánchez-Madrid, V. Andrés)
- 2011 Best Oral Communication Award, Annual Meeting Thrombosis Group (Spanish Society of Cardiology), Murcia (presented by V. Andrés) (authors: C. Silvestre, P. Fernández, Ó. Pello, R. Viana, C. Indolfi, C. Rodríguez, R. Rodríguez-Calvo, P. Martín-Fuentes, M. Solanas-Barca, F. Civeira, G. Bauriedel, R. Hutter, V. Fuster, B. Ibáñez, F.J. Chaves, J. Martínez-González, V. Andrés)
- 2013 Basic Research Poster Award, The Progeria Research Foundation Scientific Workshop 2013, Bethesda, US (presented by R. Villa-Bellosta) (authors: Villa-Bellosta, R, Rivera, J, Osorio, FG, López-Otín, C, Andrés, V)

MEMBERSHIP SCIENTIFIC SOCIETIES

- 1997-2008 American Association for the Advancement of Science
- 2007 International Society for Heart Research
- 2009-2010 Spanish Society of Pharmacology
- 1998-present Frontiers in Bioscience Society of Scientists
- 2001-present Spanish Society of Biochemistry and Molecular Biology
- 2001-present Spanish Society of Atherosclerosis
- 2003-present Spanish Society of Cardiology
- 2003-present European Society of Cardiology
- 2003-present American Heart Association, Council of Atherosclerosis, Thrombosis and Vascular Biology
- 2009-present Heart Failure Association of the European Society of Cardiology

Accreditation for the handling of experimental animals (Royal Decree 1201/2005): Categories C and D1 approved by the Spanish Ministry of Agriculture, Fishing and Food

PARTICIPATION IN COMMITTEES AND MANAGEMENT ACTIVITIES

i. Advisory Panels and Scientific Committees

- 1999-2009 Scientist in Charge of Animal Facility, Biomedical Institute of Valencia (IBV), Spanish Council for Scientific Research (CSIC), Spain
- 2003-2006 Member of the Scientific Management Board, Cardiovascular Disease Research Network (RECAVA), Institute of Health Carlos III (Instituto de Salud Carlos III)
- 2005 Ad hoc member of the board for the selection of the Director of the Department of Medicine, National Research Council (Consiglio Nazionale delle Ricerche), Italy
- 2005-2009 International Partner, Research Program on Cardiovascular Disease Risk Factors (PIFRECV), University of Talca, Chile
- 2005-2010 Member of the External Advisory Committee, Programme Research Project on Cardiovascular Risk Factors (PIFRECV), University of Talca, Chile
- 2007-2009 International Partner, Research Group 'MAOLAT' (antithrombotic and lipoprotein antioxidative molecules) (Coordinator: Dr. Iván Palomo G), University of Talca, Chile
- 2008-2012 Member of the Management Board, Cardiovascular Disease Research Network (RECAVA), Institute of Health Carlos III (Instituto de Salud Carlos III)
- 2008-2012 Member of the Educational Board, Cardiovascular Disease Research Network (RECAVA), Institute of Health Carlos III (Instituto de Salud Carlos III)
- 2009-2014 President, Commission of Animal Facility and Transgenesis, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)
- 2012 International Advisory Committee, International Conference on Recent Trends in Atherosclerosis and 25th Annual Conference of the Indian Society for Atherosclerosis Research (ISARCON-2012)
- 2012 Member of the Scientific Committee, CNIC Conference "Vascular Inflammation, aging and imaging", CNIC
- 2011-2014 Member of the Research Committee, CNIC
- 2012-present Member of the Advanced Imaging Committee, CNIC
- 2013-present Member of the Biobank Scientific Committee, CNIC
- 2013-present International Partner, Research Program of Interdisciplinary Excellence on Healthy Aging (PIEI-ES), University of Talca, Chile
- 2013-present Member of the Executive Committee Working Group BIOVASC-SEA, Spanish Society of Arteriosclerosis
- 2013-present Member of the Educational Board, Cardiovascular Research Network (RiC), Institute of Health Carlos III (Instituto de Salud Carlos III)
- 2015-present Member of the Operational Committee, CNIC
- 2015-present Member of the Medical Research Committee, Progeria Research Foundation

ii. Editorial Activities

- 1996-1999 Editorial Advisory Board, *Italian Review Medical & Surgical Research*
- 2001-2005 Editorial Advisory Board, *Cardiología Práctica*
- 2004-present Managing Editor, *Frontiers Bioscience*

- 2007-present Editorial Advisory Board, *Cardiología Práctica*
- 2007-present Editorial Advisory Board, *The Open Genomics Journal*
- 2007-present Editorial Advisory Board, *The Open Pathology Journal*
- 2010-present International Advisory Board, *Revista Médica del Maule*
- 2016-present Editorial Board, *Frontiers in Cardiovascular Medicine*

iii. Participation in peer-reviewed activities

Reviewer of Research Grants / Fellowships / Awards / Communications / Scientific courses

- 1997 Research Peer Review Committee, American Heart Association (Massachusetts Affiliate)
- 1999-present Ad hoc reviewer, National Evaluation and Foresight Agency (ANEP), Spain
- 2003 Member of the Panel for the evaluation of research projects of the National Programme of Health, Subprogramme of Biomedicine, Spanish Ministry of Science and Technology
- 2003-2004 Agency for University and Research Grants, Regional Government of Catalunya, Spain
- 2004 Israel Science Foundation
- 2004 Member of the "Panel of International Reviewers", Strategic Programme "Micro and nanotechnological platforms for advanced medical diagnostic and new therapeutic procedures", Italian Ministry of Innovation, University and Research
- 2004- 2006 Member of the Commission for Evaluation number 502 (Topic: Cardiovascular Disease), Institute of Health Carlos III (Instituto de Salud Carlos III), Spanish Ministry of Health
- 2005 Agency of Science and Technology, Portugal
- 2005 National Research Foundation, Belgium
- 2005 Evaluation Expert of EU Projects, Panel of "Major Diseases" (Representative of the Consensus Group Cardiovascular Disease), FP VI European Union
- 2005 Member of the "Panel of International Reviewers", Strategic Programme "Development of innovative technologies of genetic mapping in the sector of heart diseases", Italian Ministry of Innovation, University and Research
- 2005 Member of the Panel for the scientific-technological follow-up of research projects, National Programme of Biomedicine, Ministry of Education and Science, Spain
- 2005 Member of the Panel for the evaluation of research projects of the National Programme of Health, Subprogramme of Biomedicine, Spanish Ministry of Education and Science
- 2005 Member of the Panel for the evaluation of "Ramón y Cajal" and "Juan de la Cierva" research contracts for young investigators (Programme of Molecular, Cellular and Genetic Biology), Spanish Ministry of Education and Science
- 2005-2006 Evaluation Expert of EU Projects, Consensus group Cardiovascular Disease, FP VI European Union
- 2006 Member of the "Panel of International Reviewers", Area: "Cardiovascular Medicine", Italian Institute of Health, Italian Ministry of Health
- 2006 Member of the "Panel of International Reviewers", Strategic Programme "New applications of biomedical industry", Italian Ministry for University and Research

- 2006 Member of the Panel for the evaluation of "Ramón y Cajal" research contracts for young group leaders (Programme of Molecular, Cellular and Genetic Biology), Spanish Ministry of Education and Science
- 2006 Member of the Panel for the evaluation of research applications, Programme of R&D activities, Regional Government of Madrid
- 2007 Austrian Science Fund, Austria
- 2007 AMSUD-Pasteur Institute, France
- 2007-2011 Assistant, Coordination Team of Biomedicine, National Evaluation and Foresight Agency (ANEP), Spain
- 2009 Member of the Panel for the evaluation of fellowships, Spanish Society of Cardiology
- 2009 Member of the Panel for the selection of communications for the National Meeting of the Spanish Society of Cardiology
- 2009-2010 Member of the Panel for the selection of "Awards Fundación Biogen Idec for Young Investigators" ("Premios Fundación Biogen Idec Jóvenes Investigadores")
- 2012 Evaluation Expert, Israel Science Foundation, Israel
- 2012 Member of the Panel for the selection of communications in Cell Biology, National Meeting of the Spanish Society of Cardiology
- 2012 Assistant, Coordination Team of Biomedicine for evaluation of FIS2012 projects (Cardiovascular Panel), National Evaluation and Foresight Agency (ANEP)
- 2013 Ad hoc reviewer, Andalusian Agency for Knowledge
- 2014 Member of the Panel for the evaluation of "Ramón y Cajal" research contracts for young group leaders (Programme of Biomedicine), Spanish Ministry of Economy and Competitiveness
- 2014 Member of the Panel for the evaluation of grant proposals in Biomedicine (Cardiology), Fundación BBVA
- 2014 Chair of the Panel for the evaluation of postdoctoral researchers within the CNIC IPP (International Postdoctoral Programme), co-funded by the European Union

Ad hoc reviewer for scientific journals

Acta Physiol., Aging Cell, Am. J. Hypert., Am. J. Pathol., Am. J. Physiol., Arterioscl. Thromb. Vasc. Biol., Blood, Br. J. Pharmacol., Cardiovasc. Res., Cell Death Dis., Cell Prolif., Circulation, Circ. Res., Curr. Opin. Cell Biol., Endocrinology, Eur. Heart J., Exp. Cell Res., Exp. Gerontol., Exp. Physiol., Expert Opin. Ther. Patents, Expert Opin. Ther. Targets, FASEB J., FEBS Lett., Free Rad. Biol. Med., Front. Biosc., Gene, Hum. Gene Ther., Hypert. Res., Int. J. Cardiol., J. Am. Coll. Cardiol., J. Cardiovasc. Pharmacol., J. Cardiovasc. Med., J. Cell Biol., J. Cell. Mol. Cardiol., J. Cell. Mol. Med., J. Cell Physiol., J. Clin. Invest., J. Vasc. Res., Mol. Cell. Biol., Oncogene, Open Gen. J., PLoS ONE, Sci. Trans. Med., Thromb. Haemost., Trends Mol. Med.,

Ad hoc reviewer for databases

Targeted Protein Database (Current Biodata, <http://www.currentbiodata.com/products/tpdb.html>)

PARTICIPATION IN COMPETITIVE RESEARCH PROJECTS

- 1997-1999 Restenosis and control of vascular myocyte proliferation (RO1 HL57519). Agency: National Institutes of Health. PI: V. Andrés
- 1997-1998 Age-dependent control of vascular smooth myocyte growth (RO3 AG15227). Agency: National Institutes of Health. PI: V. Andrés
- 1998-2000 Age-related mechanisms underlying enhanced arteriosclerosis (Grant-in-Aid 9860022T). Agency: American Heart Association (Massachusetts Affiliate). PI: V. Andrés
- 1998-2001 Age-dependent alterations in smooth muscle cell proliferation after angioplasty (PM97-0136). Agency: Ministry of Education and Culture. PI: V. Andrés
- 1999-2000 Relative contribution of smooth muscle cell proliferation and reendothelialization to neointimal thickening after acute mechanical vascular injury (99100). Agency: US-Spain Science and Technology Program 1999. PIs: V. Andrés, J.M. Isner
- 1999-2001 Hormonal control of LDL oxidation in postmenopausal women and role of the expression and functional relevance of hsp27 and estrogen receptor α in endothelial and vascular smooth muscle cells (1FD97-1035-C02-02). Agency: Ministry of Education and Culture. PI: V. Andrés
- 2001-2004 Cell cycle and atherosclerosis: Regulatory mechanisms and pathological implications (Ref.: SAF2001-2358). Agency: Ministry of Science and Technology. PI: V. Andrés
- 2002 Support for cooperative research groups (CTGCA/2002/04, Project 2). Agency: Regional Government of Valencia. PI: V. Andrés
- 2002-2003 Functional and molecular characterization of the interaction between the protooncogen c-fos and the structural protein lamin A: Implications for cardiovascular disease (GV01-488). Agency: Regional Government of Valencia. PI: V. Andrés
- 2002-2004 Proteomics to identify novel biomarkers of cardiovascular disease (Programme "Improving the human research potential and the socio-economic knowledge base", Contract No HPMD-CT-2001-00110). Agency: Directorate General Research, European Commission. PI: V. Andrés
- 2002-2004 Role of the growth suppressor protein p27 during ischemic cardiomyopathy (SAF2002-1443). Agency: Ministry of Science and Technology. PI: V. Andrés
- 2003-2004 Regulation of the growth suppressor protein p27 in relation to atherosclerosis (Programme "Improving the human research potential and the socio-economic knowledge base", Contract No HPMF-CT-2002-02148). Agency: Directorate General Research, European Commission. PI: V. Andrés
- 2003-2006 Risk Factors, evolution and treatment of cardiovascular diseases and their molecular and cellular mechanisms (Network of Excellence 'RECAVA', C03/01). Agency: Institute of Health Carlos III (Instituto de Salud Carlos III). PI: V. Andrés
- 2004-2005 Molecular control of atherosclerosis and development of novel therapeutic interventions (GV04B-288). Agency: Regional Government of Valencia. PI: V. Andrés
- 2004-2005 Functional and structural proteomics and genomics of human pathologies (R&D group of excellence, GRUPOS03/072). Agency: Regional Government of Valencia. PI: V. Andrés
- 2004-2007 Molecular basis of atherosclerosis induced by hypercholesterolemia and diabetes: Identification of novel pathological markers and therapeutic targets using genomic and proteomic approaches (SAF2004-03057). Agency: Ministry of Education and Science. PI: V. Andrés
- 2006 Identification of genes involved in atherosclerosis induced by type 2 diabetes. Agency: Spanish Society of Cardiology (Research Grant Novartis 2006). PI: V. Andrés
- 2006 Risk Factors, evolution and treatment of cardiovascular diseases and their molecular and cellular mechanisms (RECAVA) (PI050542). Agency: Institute of Health Carlos III (Instituto de Salud Carlos III). PI: V. Andrés
- 2006-2007 Molecular basis of atherosclerosis induced by hypercholesterolemia and type 2 diabetes (Programme "Structuring the European Research Area – Human Resources and Mobility",

- Contract No FP6-MEIF-CT-2005-024393). Agency: Directorate General Research, European Commission. PI: V. Andrés
- 2007-2010 Novel cellular and molecular mechanisms of regulation of the atheroprotective protein p27 and possible diagnostic applications. Agency: Ramón Areces Foundation. PI: V. Andrés
- 2007-2010 Molecular and genetic basis of atherosclerosis and associated cardiovascular disease: Basic and translational aspects (SAF2007-62110). Agency: Ministry of Science and Education. PI: V. Andrés
- 2007-2012 Risk Factors, evolution and treatment of cardiovascular diseases and their molecular and cellular mechanisms (RECAVA, RD06/0014/0021). Agency: Institute of health Carlos III (Instituto de Salud Carlos III). PI: V. Andrés
- 2011-2013 Molecular and genetic mechanisms of cardiovascular disease and aging: Basic and clinical approaches (SAF2010-16044). Agency: Ministry of Science and Innovation. PI: V. Andrés
- 2012-2014 Quantification of farnesylated progerin and identification of genes that activate aberrant LMNA splicing in HGPS (Innovator Award PRF 2012-42). Agency: The Progeria Research Foundation. PI: V. Andrés
- 2012-2015 LiPhos - Living Photonics: Monitoring light propagation through cells (STREP Project, Grant Agreement No. 317916. Coordinator: Andreu Llobera. CSIC). Agency: Directorate General Research, European Commission. PIs: V. Andrés, V. Fuster, B. Ibáñez
- 2013-2016 Network of Cardiovascular Diseases (RETICs Programme, RD12/0042/0028). Agency: Institute of Health Carlos III (Instituto de Salud Carlos III). PI: V. Andrés
- 2014-2016 Molecular and cellular mechanisms underlying aging and age-related cardiovascular disease (SAF2013-46663-R). Agency: Ministry of Economy and Competitiveness. PI: V. Andrés
- 2014-2017 Generation of a HGPS knock-in pig model to expedite the development of effective clinical applications (Established Investigator Award 2014-52). Agency: The Progeria Research Foundation. PI: V. Andrés
- 2016-2018 Role of advanced glycation end-products (AGEs) in ischemia-reperfusion injury of the aged and diabetic heart: New insights from mouse and human studies (122/C/2015). Agency: Fundació la Marató de TV3. PI CNIC: V. Andrés (Coordinator: M. Ruiz-Meana).
- 2016-2019 Award "Centro de Excelencia Severo Ochoa" (SEV-2015-0505). Scientific Director: V. Andrés
- 2017-2019 Exploring new pathways in age-related heart diseases (ERA-CVD joint transnational call 2016). Agency: Directorate General Research, European Commission. PIs: V. Andrés, V. Fuster
- 2017-2019 Role of nuclear A-type lamins in cardiovascular disease and aging (SAF2016-79490-R). Agency: Ministry of Economy and Competitiveness. PI: V. Andrés

PARTICIPATION IN RESEARCH CONTRACTS OF SPECIAL RELEVANCE WITH COMPANIES AND/OR PRIVATE OR PUBLIC FUNDING BODIES

- 2003-2006 Identification of novel biomarkers of atherosclerosis by proteomic techniques. Agency: INDAS Laboratories. PI: V. Andrés
- 2005-2009 Identification of genetic polymorphisms in p27, p21 and p57 as risk factors of restenosis after implantation of coronary stents. Agency: FINA BIOTECH. PI: V. Andrés
- 2012 Validation of genetic markers of restenosis risk after implantation of coronary stents. Agency: FINA BIOTECH. PI: V. Andrés

PUBLICATIONS IN PEER-REVIEWED JOURNALS

NOTES: Publications are original research article unless stated otherwise

* indicate co-senior authors

1. Iglesias, R, **Andrés, V**, Castellà, J, Alemany, M. Lack of effect on the onset of cafeteria feeding on growth and thermogenesis in young rats. *Nutr. Rep. Int.* 34:229-239 (1986).
2. **Andrés, V**, Carreras, J, Cussó, R. Activation of muscle phosphofructokinase by glucose 1,6-bisphosphate and fructose 2,6-bisphosphate is differently affected by other allosteric effectors and by pH. *Biochem. Biophys. Res. Comm.* 157:664-669 (1988).
3. **Andrés, V**, García-Salguero, L, Gómez, ME, Aragón, JJ. Allosteric inhibition of *Dictyostelium discoideum* fructose-1,6-bisphosphatase by fructose-2,6-bisphosphate. *FEBS Lett.* 241:51-54 (1988).
4. **Andrés, V**, Cussó, R, Carreras, J. Distribution and developmental transition of phosphoglycerate mutase and creatine phosphokinase isozymes in rat muscles of different fiber-type composition. *Differentiation* 41:72-77 (1989).
5. **Andrés, V**, Cussó, R, Carreras, J. Effect of denervation on the distribution and developmental transition of phosphoglycerate mutase and creatine phosphokinase isozymes in rat muscles of different fiber-type composition. *Differentiation* 43:98-103 (1990).
6. **Andrés, V**, Carreras, J, Cussó, R. Regulation of muscle phosphofructokinase by physiological concentrations of bisphosphorylated hexoses. Effect of alkalization. *Biochem. Biophys. Res. Comm.* 172:328-334 (1990).
7. **Andrés, V**, Schultz, V, Tornheim, K. Oscillatory synthesis of glucose 1,6-bisphosphate and frequency modulation of glycolytic oscillations in skeletal muscle extracts. *J. Biol. Chem.* 265:21441-21447 (1990).
8. Torheim, K, **Andrés, V**, Schultz, V. Modulation by citrate of glycolytic oscillations in skeletal muscle extracts. *J. Biol. Chem.* 266:15675-15678 (1991).
9. Bassols, A, **Andrés, V**, Ballarín, M, Mahy, N, Carreras, J, Cussó, R. Identification of guanine and adenine nucleotides as activators of glucose-1,6-bisphosphatase activity from rat skeletal muscle. *Arch. Biochem. Biophys.* 291:121-125 (1991).
10. Cadefau, JA, **Andrés, V**, Carreras, J, Vernet, M, Grau, JM, Urbano-Máquez, A, Cussó, R. Glucose 1,6-bisphosphate and fructose 2,6-bisphosphate in muscle from healthy humans and chronic alcoholic patients. *Alcohol & Alcoholism* 27:253-256 (1992).
11. **Andrés, V**, Nadal-Ginard, B, Mahdavi, V. Clox, a mammalian homeobox gene related to *Drosophila cut*, encodes DNA binding regulatory proteins differentially expressed during development. *Development* 116:321-324 (1992).
12. McDermott, JC, Cardoso, MC, Yu, Y-Y, **Andrés, V**, Leifer, D, Krainc, D, Lipton, S, Nadal-Ginard, B. hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors. *Mol. Cell. Biol.* 13:2564-2577 (1993).
13. **Andrés, V**, Chiara, MD, Mahdavi, V. A new bipartite DNA-binding domain: cooperative interaction between the cut repeat and homeodomain of the cut-homeoproteins. *Genes Dev.* 8:245-257 (1994).
14. **Andrés, V**, Cervera, M, Mahdavi, V. Determination of the consensus binding site for MEF2 expressed in muscle and brain reveals tissue-specific sequence constraints. *J. Biol. Chem.* 270: 23246-23249 (1995).

15. **Andrés, V**, Fisher, S, Wearsch, P, Walsh, K. Regulation of *Gax* homeobox gene transcription by a combination of positive factors including myocyte-specific enhancer factor 2. *Mol. Cell. Biol.* 15: 4272-4281 (1995).
16. Guo, K, Wang, J, **Andrés, V**, Smith, RC, Walsh, K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. *Mol. Cell. Biol.* 15: 3823-3829 (1995).
17. **Andrés, V**, Walsh, K. Myogenin expression, cell cycle withdrawal and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. *J. Cell Biol.* 132: 657-666 (1996).
18. **Andrés, V**, Carreras, J, Cussó, R. Myofibril-bound muscle phosphofructokinase is less sensitive to inhibition by ATP than the free enzyme, but retains its sensitivity to stimulation by bisphosphorylated hexoses. *Int. J. Biochem. Cell Biol.* 28: 1179-1184 (1996).
19. Walsh, K, Guo, K, Wang, J, **Andrés, V**. p21 regulation and function during myogenesis. *Mol. Cell. Diff.* 4: 17-31 (1996) [Review].
20. Wei, GL., Krasinski, K, Kearney, M, Isner, JM, Walsh, K, **Andrés, V**. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. *Circ. Res.* 80: 418-426 (1997).
21. Skopicki, HA, Lyons, GE., Schatteman, G, Smith, RC, **Andrés, V**, Schirm, S, Isner, JM, Walsh, K. Embryonic expression of the *Gax* homeodomain protein in cardiac, smooth and skeletal muscle. *Circ. Res.* 80: 452-462 (1997).
22. Chen, D, Krasinski, K, Chen, D, Sylvester, A, Chen, J, Nisen, PD, **Andrés, V**. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27^{KIP1}, an inhibitor of neointima formation in the rat carotid artery. *J. Clin. Invest.* 99: 2334-2341 (1997).
23. Kearney, M, Pieczek, A, Haley, L, Losordo, DW, **Andrés, V**, Schainfield, R, Rosenfield, K, Isner, JM. Histopathology of in-stent restenosis. *Circulation.* 95: 1998-2002 (1997).
24. Guo, K, **Andrés, V**, Walsh, K. Nitric oxide-induced downregulation of cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. *Circulation* 20: 2066-2072 (1998).
25. Garriga, J, Limón, A, Mayol, X, Rane, SG, Albrecht, JH, Reddy, EP, **Andrés, V**, Graña, X. Differential regulation of pocket proteins during cell proliferation and differentiation. *Biochem. J.* 333: 645-654 (1998).
26. Sylvester, A, Chen, D, Krasinski, K, **Andrés, V**. Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation. *J. Clin. Invest.* 101: 940-948 (1998).
27. **Andrés, V**. Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis. *Int. J. Mol. Med.* 2: 81-89 (1998) [Review].
28. *Spyridopoulos, I, Andrés, V. Control of vascular smooth muscle and endothelial cell proliferation and its implication in cardiovascular disease. Front. Biosc.* 3: d269-d287 (1998) [Review].
29. Chen, D, Guo, K, Yang, J, Frazier, WA, Isner, JM, **Andrés, V**. Vascular smooth muscle cell growth arrest upon blockade of thrombospondin-1 requires p21^{Cip1/WAF1}. *Am. J. Physiol. – Heart C.* 277: H1100-H1106 (1999).

30. Chen, D, Asahara, T, Krasinski, K, Witzenbichler, B, Yang, J, Magner, M, Kearney, M, Frazier, WA, Isner, JM, **Andrés, V.** Antibody blockade of thrombospondin-1 accelerates reendothelialization and reduces neointima formation in balloon-injured rat carotid artery. *Circulation* 100: 849-854 (1999).
- Editorial:** Silverstein, RL, Nachman, RL. Angiogenesis and atherosclerosis. The mandate broadens. *Circulation* 100:783-785 (1999).
31. Rivard, A, Principe, N, **Andrés, V.** Age-dependent increase in vascular smooth muscle cell proliferation, cyclin A expression and c-fos activity. A potential link between aging and atherosclerosis. *Cardiovasc. Res.* 45: 1026-1034 (2000).
32. Rivard, A, **Andrés, V.** Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. *Histol. Histopathol.* 15: 557-571 (2000) [Review].
33. Pérez-Roger, I, Ivorra, C, Díez, A, Cortés, MJ, Poch, E, Sanz-González, SM, **Andrés, V.** Inhibition of cellular proliferation by drug targeting of cyclin-dependent kinases. *Curr. Pharm. Biotechnol.* 1: 107-116 (2000) [Review].
34. Sanz-González, SM, Poch, E, Pérez-Roger, I, Díez-Juan, A, Ivorra, C, **Andrés, V.** Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease. *Front. Biosc.* 5: d619-628 (2000) [Review].
35. **Andrés, V.** Ureña, J, Poch, E, Chen, D, Goukassian, D. The role of Sp1 in the induction of p27 gene expression in vascular smooth muscle cells in vitro and after balloon angioplasty. *Arterioscl. Thromb. Vasc. Biol.* 21: 342-347 (2001).
36. Goukassian, D, Sanz-González, SM, Pérez-Roger, I, Font de Mora, J, Ureña, J, **Andrés, V.** Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation. *Br. J. Pharmacol.* 132: 1597-1605 (2001).
37. Díez-Juan, A, **Andrés, V.** The growth suppressor p27^{Kip1} protects against diet-induced atherosclerosis. *FASEB J.* 15: 1989-1995 (2001).
38. Goukassian, D, Díez-Juan, A, Asahara, T, Schratzberger, P, Silver, M, Murayama, T, Isner, JM, **Andrés, V.** Overexpression of p27^{Kip1} by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. *FASEB J.* 15: 1877-1885 (2001).
39. Cortés, MJ, Díez-Juan, A, Pérez, P, Pérez-Roger, I, Arroyo-Pellicer, R, **Andrés, V.** Increased early atherogenesis in young versus old hypercholesterolemic rabbits by a mechanism independent of arterial cell proliferation. *FEBS Lett.* 522: 99-103 (2002).
40. López-Sánchez, E, Francés-Muñoz, E, Díez-Juan, A, **Andrés, V.** Menezo, JL, Pinazo-Durán, MD. Optic nerve alterations in apolipoprotein E deficient mice. *Eur. J. Ophthalmol.* 13: 560-565 (2003).
41. Castro, C, Díez-Juan, A, Cortés, MJ, **Andrés, V.** Distinct regulation of mitogen-activated protein kinases and p27^{Kip1} in smooth muscle cells from different vascular beds: A potential role in establishing regional phenotypic variance. *J. Biol. Chem.* 278: 4482-4490 (2003).
42. Díez-Juan, A, **Andrés, V.** Coordinate control of proliferation and migration by the p27^{Kip1}/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. *Circ. Res.* 92: 402-410 (2003).
- Editorial:** Bornfeldt, K. The cyclin-dependent kinase pathway moves forward. *Circ. Res.* 92:345-347 (2003).
43. Gascón-Irún, M, Sanz-González, SM, **Andrés, V.** Gene therapy antiproliferative strategies against cardiovascular disease. *Gene Ther. Mol. Biol.* 7: 75-89 (2003) [Review].
44. Ivorra, C, Samyn, H, Edo, MD, Castro, C, Sanz-González, SM, Díez-Juan, A, **Andrés, V.** Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease. *Curr. Pharm. Biotechnol.* 4: 21-37 (2003) [Review].

45. **Andrés, V**, Castro, C. Antiproliferative strategies for the treatment of vascular proliferative disease. *Curr. Vasc. Pharmacol.* 1: 85-98 (2003) [Review].
46. Díez-Juan, A, Castro, C, Edo, MD, **Andrés, V**. Role of the growth suppressor p27^{Kip1} during vascular remodeling. *Curr. Vasc. Pharmacol.* 1: 99-106 (2003) [Review].
47. Edo, MD, Roldán, M, **Andrés, V**. Cyclin-dependent protein kinases as therapeutic targets in cardiovascular disease. *Expert Opin. Ther. Patents* 13: 579-588 (2003) [Review].
48. Castro, C, Campistol, JM, Sancho, D, Sánchez-Madrid, F, Casals, E, **Andrés, V**. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27^{Kip1}-independent pathway. *Atherosclerosis* 172: 33-40 (2004).
49. Díez-Juan, A, Pérez, P, Aracil, M, Sancho, D, Bernad, A, Sánchez-Madrid, F, **Andrés, V**. Selective inactivation of p27^{Kip1} in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. *Blood* 103:158-161 (2004).
50. Poch, E, Carbonell, P, Franco, S, Díez-Juan, A, Blasco, MA, **Andrés, V**. Short telomeres protect from diet-induced atherosclerosis in apolipoprotein E-null mice. *FASEB J.* 18:418-420 (2004).
51. Sanz-González, SM, Castro, C, Pérez, P, **Andrés, V**. Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression *Biochem. Biophys. Res. Comm.* 317: 972-979 (2004).
52. González, P, Díez-Juan, A, Coto, E, Álvarez, V, Reguero, JR, Batalla, A, **Andrés, V**. A single-nucleotide polymorphism in the human p27^{Kip1} gene (-838 C>A) affects basal promoter activity and the risk of myocardial infarction. *BMC Biology* 2:5 (2004).
53. Sanz-González, SM, Cano, A, Valverde, MA, Hermenegildo, C, **Andrés, V**. Drug targeting of estrogen receptor signaling in the cardiovascular system: Preclinical and clinical studies. *Curr. Med. Chem. Cardiovasc. Hematol. Agents* 2: 107-122 (2004) [Review].
54. Kubicek, M, Sanz-González, SM, Verdeguer, F, **Andrés, V**. Proteomics to identify novel biomarkers and therapeutic targets in cardiovascular disease. *Lett. Drug Design Discov.* 1: 237-246 (2004) [Review].
55. Serrano, AL, **Andrés, V**. Telomeres and cardiovascular disease. Does size matter? *Circ. Res.* 94: 575-584 (2004) [Review].
56. **Andrés, V**. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential *Cardiovasc. Res.* 63:11-21 (2004) [Review].
57. **Andrés, V**. Atherogenic role of the type EIIIA fibronectin domain. *Blood* 104:3-4 (2004) [Editorial].
58. **Andrés, V**. Unexpected proatherogenic properties of p21: Beyond cell cycle control? *Circulation* 110:3749-3752 (2004) [Editorial].
59. Castro, C, Campistol, JM, Baretino, D, **Andrés, V**. Transcriptional profiling of early onset diet-induced atherosclerosis in apolipoprotein E-deficient mice. *Front. Biosc.* 10:1932-1945 (2005).
60. Edo, MD, **Andrés, V**. Aging, telomeres, and atherosclerosis. *Cardiovasc. Res.* 66: 213-221 (2005) [Review].
61. Ivorra, C, Kubicek, M, González, JM, Sanz-González, SM, Álvarez-Barrientos, A, O'Connor, JE, Burke, B, **Andrés, V**. A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. *Genes Dev.* 20:307-320 (2006).

Commentaries:

Control transcriptional por secuestro de c-Fos. **Boletín de la Sociedad Española de Bioquímica y Biología Molecular** 147: 46 (2006)

Faculty 1000 Biology (<http://www.f1000biology.com/article/id/1030947/evaluation>)

62. Sanz-González, SM, Melero-Fernández de Mera, R, Malek, NP, **Andrés, V.** Atheroma development in apolipoprotein E-null mice is not regulated by phosphorylation of p27^{Kip1} on threonine 187. **J. Cell. Biochem.** 97:735-743 (2006).
63. **Andrés, V,** Gascón-Irún, M, Pandolfi, PP, González-Navarro, H. Atheroma development in apolipoprotein E-null mice is not affected by partial inactivation of PTEN. **Front. Biosci.** 11:2739-2745 (2006).
64. González, JM, **Andrés, V.** Cytostatic gene therapy for occlusive vascular disease. **Expert Opin. Ther. Patents** 16:507-522 (2006) [Review].
65. **Andrés, V,** Castro, C, Campistol, JM. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. **Nephrol. Dial. Transplant.** 21 Suppl 3:iii14-iii17 (2006) [Review].
66. Fuster, JJ, **Andrés, V.** Telomere biology and cardiovascular disease. **Circ. Res.** 99:1167-1180 (2006). **This article is one of five reviews comprising a thematic series on "Biological Roles of Senescence in Cardiovascular Disease".**
67. González-Navarro, H, Burks, D, **Andrés, V.** Murine models to investigate the influence of diabetic metabolism on the development of atherosclerosis and restenosis. **Front. Biosci.** 12:4439-4455 (2006) [Review].
68. González-Navarro, H, Vila-Caballer, M, Pastor, MF, Vinué, A, White, MF, Burks, D, **Andrés, V.** Plasma insulin levels predict the development of diabetic atherosclerosis when IRS-2 deficiency is combined with severe hypercholesterolemia. **Front. Biosci.** 12:2291-2298 (2007).
69. Rodríguez, I, Coto, E, Reguero, JR, González, P, **Andrés, V,** Lozano, I, Martín, M, Álvarez, V, Moris, C. Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction. **Cell Cycle** 6:620-625 (2007).
70. Sanz-González, SM, Barquín, L, García-Cao, I, Roqué, M, González, JM, Fuster, JJ, Castells, MT, Flores, JM, Serrano, M, **Andrés, V.** Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis **Cardiovasc. Res.** 75:803-812 (2007).
71. Verdeguer, F, Castro, C, Kubicek, M, Pla, M, Vila-Caballer, M, Vinué, A, Civeira, F, Pocoví, M, Calvete, JJ, **Andrés, V.** Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation. **Cardiovasc. Res.** 76:340-350 (2007).
72. Fuster, JJ, Sanz-González, SM, Moll, U, **Andrés, V.** Classic and novel roles of p53: prospects for anticancer therapy. **Trends Mol. Med.** 13:192-199 (2007) [Review].
73. Fuster, JJ, Díez, J, **Andrés, V.** Telomere dysfunction in hypertension. **J. Hypertension** 25:2185-2192 (2007) [Review].
74. González-Navarro, H, Burks, DJ, **Andrés, V.** Murine models to investigate the influence of diabetic metabolism on the development of atherosclerosis and restenosis. **Front. Biosci.** 12:4439-4455 (2007) [Review].

75. González, JM, Navarro, A, Casar, B, Crespo, P, **Andrés, V.** Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2 and c-Fos at the nuclear envelope. *J. Cell. Biol.* 183: 653-666 (2008).
- Commentary:** Faculty 1000 Biology (<http://www.f1000biology.com/article/id/1137896/evaluation>)
76. González-Navarro, H, Vinué, A, Vila-Caballer, M, Fortuño, A, Beloqui, O, Zalba, G, Burks, D, Díez, J, **Andrés, V.** Molecular mechanisms of atherosclerosis in metabolic syndrome: Role of reduced IRS2-dependent signaling. *Arterioscl. Thromb. Vasc. Biol.* 28:2187-2194 (2008).
77. Gómez, M, Sanz-González, SM, Naim Abu Nabah, Y, Lamana, A, Sánchez-Madrid, F, **Andrés, V.** Atherosclerosis development in apolipoprotein E-null mice deficient for CD69. *Cardiovasc. Res.* 81:197-205 (2009).
78. **Andrés, V,** González, JM. Role of A-type lamins in signaling, transcription and chromatin organization. *J. Cell Biol.* 187:945-957 (2009) **[Review]**.
79. González-Navarro, H, Naim Abu Nabah, Y, Vinué, A, Andrés-Manzano, MJ, Collado, M, Serrano, M, **Andrés, V.** p19^{Arf} deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. *J. Am. Coll. Cardiol.* 55:2258-2268 (2010).
- Editorial:** Wessely, R. Atherosclerosis and cell cycle: Put the brakes on! Critical role for cyclin-dependent kinase inhibitors. *J. Am. Coll. Cardiol.* 55:2269-2271 (2010).
- Commentary:** DeMaria et al. Highlights of the Year in JACC 2010. *J. Am. Coll. Cardiol.* 57:480-514 (2011)
80. Fuster, JJ, González, JM, Edo, MD, Viana, R, Boya, P, Cervera, J, Verges, M, Rivera, J, **Andrés, V.** Tumor suppressor p27^{Kip1} undergoes endo-lysosomal proteolysis through its interaction with sorting nexin 6. *FASEB J.* 24:2998-3009 (2010).
81. Rodríguez, J, Calvo, F, González, JM, Casar, B, **Andrés, V,** Crespo, P. ERK1/2 MAP kinases promote cell cycle entry by rapid, kinase-independent disruption of retinoblastoma-lamin A complexes. *J. Cell Biol.* 191:967-979 (2010).
- Special mention:** Rb gets ERK'd by competition. *J. Cell Biol.* 191:894 (2010).
- Commentary:** Adler, EM. ERKed about lamin A. *Sci.Signal.* 3. ec371 (2010).
82. Palomo, I, Moore-Carrasco, R, Alarcón, M, Rojas, A, España, F, **Andrés, V,** González-Navarro, H. Pathophysiology of the prothrombotic state in metabolic syndrome. *Front. Biosci.* 2:194-208 (2010) **[Review]**.
83. Fuster, JJ, Fernández, P, González-Navarro, H, Silvestre, C, Naim Abu Nabah, Y, **Andrés, V.** Control of cell proliferation in atherosclerosis: Insights from animal models and human studies. *Cardiovasc. Res.* 86:254-264 (2010) **[Review]**.
84. Fuster, JJ, **Andrés, V.** A role for miR-33 in p53 regulation: New perspectives for hematopoietic stem cell research. *Cell Cycle* 9: 3397-3398 (2010) **[Editorial]**.
85. Jiménez-Navarro, MF, Bueno, H, Alvarez-Sala, L, Rodríguez-Losada, N, **Andrés, V.** and González-Navarro, H. Insulin receptor substrate-1 expression is increased in circulating leukocytes of patients with acute coronary syndrome. *ISRN Cardiology* 2011, Article ID 740585, 5 pages doi:10.5402/2011/740585 (2011).
86. Fuster, JJ, González-Navarro, H, Vinué, A, Molina, P, Andrés-Manzano, MJ, Nakayama, KI, Nakayama, K, Díez-Juan, A, Bernad, A, Rodríguez, C, Martínez-González, J, **Andrés, V.** Deficient p27 phosphorylation at serine 10 increases macrophage foam cell formation and aggravates

- atherosclerosis through a proliferation-independent mechanism. *Arterioscl. Thromb. Vasc. Biol.* 31:2455-2463 (2011).
87. Osorio, FG, Navarro, CL, Cadiñanos, J, López-Mejía, IC, Quirós, PM, Bartoli, C, Rivera, J, Tazi, J, Guzmán, G, Varela, I, Depetris, D, de Carlos, F, Cobo, J, **Andrés, V**, De Sandre-Giovannoli, A, Freije, JMP, Lévy, N, López-Otín, C. Splicing-directed therapy in a new mouse model of human accelerated aging. *Sci. Trans. Med.* 3:106ra107 (2011).
- Editors' choice:** Splicing therapy comes of age. *Science* 334:739 (2011).
88. González, JM, Pla, D, Pérez-Sala, D, **Andrés, V**. A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy. *Front. Biosci.* 3:1133-1146 (2011) [Review].
89. Trigueros-Motos, L, González, JM, Rivera, J, **Andrés, V**. Hutchinson-Gilford progeria syndrome, cardiovascular disease and oxidative stress. *Front. Biosci.* 3:1285-1297 (2011) [Review].
90. Pello, OM, Silvestre, C, De Pizzol, M, **Andrés, V**. A glimpse on the phenomenon of macrophage polarization during atherosclerosis. *Immunobiology* 216:1172-1176 (2011) [Review].
91. González, JM, **Andrés, V**. Synthesis, transport and incorporation into the nuclear envelope of A-type lamins and inner nuclear membrane proteins. *Biochem Soc. Trans.* 39:1758-1763 (2011) [Review].
92. Fuster, JJ, Molina, P, Jovaní, D, Vinué, A, Serrano, M, **Andrés, V**. Increased gene dosage of the Ink4/Arf locus does not attenuate atherosclerosis development in hypercholesterolaemic mice. *Atherosclerosis*. 221:98-105 (2012).
93. Sorianello, E, Soriano, FX, Fernández-Pascual, S, Sancho, A, Naon, D, Vila-Caballer, M, González-Navarro, H, Portugal, J, **Andrés, V**, Palacín, M, Zorzano, A. The promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells. *Cardiovasc. Res.* 94:38-47 (2012).
- Editorial:** Knowlton, AA, Le Chen, I. Regulating a uniter: control of mitofusin 2 expression. *Cardiovasc. Res.* 94:6-7 (2012).
94. **Andrés, V**, Pello, OM, Silvestre-Roig, C. Macrophage proliferation and apoptosis in atherosclerosis. *Curr. Opin. Lipidol.* 23:429-438 (2012) [Review].
95. Pello, OM, Chèvre, R, Laoui, D, De Juan, A, Lolo, F, Andrés-Manzano, MJ, Serrano, M, Van Ginderachter, JA, **Andrés, V**. In vivo inhibition of c-Myc in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities. *PLoS One* 7:e45399. doi:10.1371/Journal.pone.0045399 (2012).
96. Wessely, R, **Andrés, V**. Limus is not limus – a proposal to adjust terminology in the context of drug-eluting stents. *J. Cardiovasc. Pharmacol.* 59:485-486 (2012) [Letter to Editor].
97. González-Navarro, H*, Vinué, A, Sanz, MJ, Delgado, M, Pozo, MA, Serrano, M, Burks, DJ, **Andrés, V***. Increased dosage of Ink4/Arf protects against glucose intolerance and insulin resistance associated with aging. *Aging Cell* 12:102-111 (2013).
98. Aguilera-Montilla, N., Chamorro, S., Nieto, C., Sánchez-Cabo, F., Dopazo, A., Fernández-Salguero, P.M., Rodríguez-Fernández, J.L., Pello, O.M., **Andrés, V.**, Cuenda, A., Alonso, B., Domínguez-Soto, A., Sánchez-Ramón, S., Corbí, A.L. Aryl Hydrocarbon Receptor contributes to the MEK/ERK-dependent maintenance of the immature state of human dendritic cells. *Blood* 121:e108-17 (2013).
99. Silvestre-Roig, C, Fernández, P, Esteban, V, Pello, OM, Indolfi, C, Rodríguez, C, Rodríguez-Calvo, R, López-Maderuelo, MD, Bauriedel, G, Hutter, R, Fuster, V, Ibáñez, B, Redondo, JM, Martínez-

- González, J, **Andrés, V.** Inactivation of NF- κ B inhibits vascular smooth muscle cell proliferation and neointima formation. *Arterioscl. Thromb. Vasc. Biol.* 33:1036-1045 (2013).
100. Trigueros-Motos, L, González-Granado, JM, Cheung, C, Fernández, P, Sánchez-Cabo, F, Dopazo, A, Sinha, S, **Andrés, V.** Embryological-origin-dependent differences in Hox expression in adult aorta and role in regional phenotypic variability *Arterioscl. Thromb. Vasc. Biol.* 33:1248-1256 (2013).
- Editorial:** Awgulewitsch, A., Majesky, M.W. Interpreting inflammation: Smooth muscle positional identity and Nuclear Factor- κ B signaling. *Arterioscler. Thromb. Vasc. Biol.* 33:1113-1115 (2013).
101. Villa-Bellosta, R, Rivera-Torres, J, Osorio, FG, Acín-Pérez, R, Enriquez, JA, López-Otín, C, **Andrés, V.** Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. *Circulation* 127:2442-2451 (2013).
- Editorial:** Leopold, J.A. Vascular calcification: An age-old problem of old age. *Circulation* 127:2380-2382 (2013).
102. Pla, D, Sanz, L, Molina-Sánchez, P, Zorita, V, Madrigal, M, Flores-Díaz, M, Alape-Girón, A, Núñez, V, **Andrés, V.,** Gutiérrez, JM, Calvete, JJ. Snake venomomics of Lachesis muta rhombeata and genus-wide antivenomics assessment of the paraspecific efficacy of two antivenoms evidence the high compositional and immunological conservation across Lachesis. *J. Proteom.* 89:112-23 (2013).
103. Zotes, T.M, Arias, C.F., Fuster, J.J., Pérez-Yagüe, S., Spada, R., Hirsch, E., Wymann, M., Carrera, A.C., **Andrés, V.,** Barber, D.F. PI3K p110 γ deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions. *PLoS One* 8:e72674 (2013).
104. Rivera-Torres, J*, Acín-Perez, R, Cabezas-Sánchez, P, Osorio, FG, Gonzalez, C, Megias, D, Cámara, C, López-Otín, C, Enriquez, JA, Luque-García, JL, **Andrés, V*.** Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labelling with amino acids in cell culture. *J. Proteom.* 91C:466-477 (2013).
105. Méndez-Barbero, N, Esteban, V, Villahoz, S, Escolano, A, Urso, K, Alfranca, A, Rodríguez, C, Sánchez, S, Osawa, T, **Andrés, V,** Martínez-González, J, Minami, T, Redondo, JM, Campanero, M. A major role for RCAN1 in atherosclerosis progression. *EMBO Mol. Med.* 5:1901-1917(2013).
106. Pello, OM, **Andrés, V.** Role of c-Myc in tumor-associated macrophages and cancer progression. *Oncolmmunology* 2:e22984 (2013) **[Commentary]**.
107. Fuentes, E, Fuentes, F, **Andrés, V,** Pello, OM, Font de Mora, J, Palomo, I. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. *Platelets* 24(4):255-62 (2013) **[Review]**.
108. Silvestre-Roig, C, Fernández, P, Mansego, ML, van Tiel, CM, Viana, R, Anselmi, CV, Condorelli, G, de Winter, RJ, Martín-Fuentes, P, Solanas-Barca, M, Civeira, F, Focaccio, A, de Vries, CJM, Chaves, FJ*, **Andrés, V*.** Genetic variants in CCNB1 associated with differential gene transcription and risk of coronary in-stent restenosis. *Circ Cardiovasc Genet.* 7:59-70 (2014).
109. Redondo, S, Navarro-Dorado, J, Ramajo, M, Medina, U, Molina-Sanchez, P, Garces, Z, Alonso, M, Reguillo, F, Rodriguez, E, **Andrés, V,** Tejerina, T. Age-dependent defective TGF-beta1 signaling in patients undergoing coronary artery bypass grafting. *J Cardiothorac Surg.* 9:24 (2014).
110. Chèvre, R, González-Granado, JM, Megens, RTA, Sreeramkumar, V, Silvestre-Roig, C, Molina-Sánchez, P, Weber, C, Soehnlein, O, Hidalgo, A*, **Andrés, V*.** High-resolution imaging of intravascular atherogenic inflammation in live mice *Circ Res.* 114:770-779 (2014).

Issue cover**“In this issue” featured article**

Editorial: Nahrendorf, M, Swirsky, F.K. Fluorescent leukocytes enter plaque on the microscope stage. *Circ Res.* 114:740-741 (2014).

111. Escudero, B., Lucas, D., Albo, C., Dhup, S., Bacher, J.W., Sánchez-Muñoz, A., Fernández, M., Rivera, J., Carmona, R.M., Fuster, C., Carreiro, C., Bernad, R., González, M.A., **Andrés, V.**, Blanco, L., Roche, E., Fabregat, I., Samper, E., Bernad, A. Polμ deficiency increases resistance to oxidative damage and delays liver aging. *PLoS ONE* 9(4):e93074 (2014).
112. González-Granado, JM*, Silvestre-Roig, C, Rocha-Perugini, V, Trigueros-Motos, L, Cibrian, D, Morlino, G, Blanco-Berrocal, M, Osorio, FG, Freije, JMP, López-Otín, C, Sánchez-Madrid, F*, **Andrés, V***. Nuclear envelope lamin-A couples actin dynamics with immunological synapse architecture and T cell activation. *Science Signal.* 7:ra37 (2014).

Issue cover

Podcast (http://podcasts.aaas.org/science_signaling/ScienceSignaling_140422.mp3)

Commentaries:

Bird L. Lamin-A links synapse to nucleus: The synapse connection. *Nat Rev Immunol* (June issue 2014)

Faculty 1000 Prime Recommendations: Dissents and Comments for [González-Granado JM et al., *Sci Signal* 2014, 7(322):ra37]. In F1000Prime, 21 May 2014; F1000Prime.com/718360131

113. **Andrés, V.** Vitamin D puts the brakes on angiotensin II-induced oxidative stress and vascular smooth muscle cell senescence. *Atherosclerosis* 236:444-447 (2014) [Invited commentary].
114. González-Granado, JM, Navarro-Puche, A, Molina-Sanchez, P, Blanco-Berrocal, M, Viana, R, Font de Mora, J, **Andrés, V.** Sorting nexin 6 enhances lamin A synthesis and its incorporation into the nuclear envelope. *PLoS ONE* 9:e115571 (2014).
115. Fernández-Murga, ML, Vinué, A, Caeiro, JR, Guede, D, Tarín, JJ, **Andrés, V**, Cano, A. The impact of estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model. *Menopause* 22:428-436 (2015)
116. Rivera-Torres, J, Guzmán-Martínez, G, Villa-Bellosta, R, Orbe, J, González-Gómez, C, Serrano, M, Díez, J, **Andrés, V***, Maraver, A*. Targeting γ-secretases protects against angiotensin II-induced cardiac hypertrophy. *J Hypertension* 33:843–850 (2015)
117. Burillo, E, Lindholt, JS, Molina-Sánchez, P, Jorge, I, Martínez-Pinna, R, Blanco-Colio, LM, Tarín, C, Torres-Fonseca, M, Esteban, M, Laustsen, J, Ramos-Mozo, P, Calvo, E, López, JA, Vega de Ceniga, M, Michel, J-B, Egido, J, **Andrés, V**, Vázquez, J, Meilhac, O, Martin-Ventura, JL. ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression. *Thromb Haemost* 113:1335-1346 (2015).
118. Arroyo, AG, **Andrés, V.** ADAMTS7 in cardiovascular disease: From bedside to bench and back again? *Circulation.* 131:1156-1159 (2015) [Invited editorial].
119. Molina-Sánchez P, Chèvre R, Rius C, Fuster JJ, **Andrés V.** Loss of p27 phosphorylation at Ser10 accelerates early atherogenesis by promoting leukocyte recruitment via RhoA/ROCK. *J Mol Cell Cardiol.* 84:84-94 (2015)
120. Vinué Á, Andrés-Blasco I, Herrero-Cervera A, Piqueras L, **Andrés V**, Burks DJ, Sanz MJ, González-Navarro H. Ink4/Arf locus restores glucose tolerance and insulin sensitivity by reducing hepatic steatosis and inflammation in mice with impaired IRS2-dependent signalling. *Biochem Biophys Acta - Mol Basis Dis.* 1852:1729-1742 (2015).

121. García-Marqués F, Trevisan-Herraz M, Martínez-Martínez S, Camafeita E, Jorge I, López JA, Méndez-Barbero N, Méndez-Ferrer S, Del Pozo MÁ, Ibáñez B, **Andrés V**, Sánchez-Madrid F, Redondo JM, Bonzon-Kulichenko E, Vázquez J. A novel systems-biology algorithm for the analysis of coordinated protein responses using quantitative proteomics. *Mol Cell Proteom (In Press)*
122. Villa-Bellosta, R, Hamczyk, MR, **Andrés, V** Alternatively activated macrophages exhibit an anti-calcifying activity dependent on extracellular ATP/pyrophosphate metabolism. *Am J Physiol - Cell Physiol* 15;310(10):C788-99. (2016)
123. Fernández-Alvira JM, Fuster V*, Dorado B, Soberón N, Flores I, Gallardo M, Pocock S, Blasco MA & **Andrés V***. Short telomere load, telomere length and subclinical atherosclerosis. The PESA study. *J Am Coll Cardiol*; 67(21):2467-2476 (2016)
- Editorial:** Ernst R, Rietzschel, Sofie Bekaert, and Tim De Meyer Telomeres and Atherosclerosis: The Attrition of an Attractive Hypothesis. *J Am Coll Cardiol*. 2016;67(21):2477-2479
124. Del Toro R, Chevre R, Rodríguez C, Ordóñez A, Martínez-González J, **Andrés V**, Mendez-Ferrer, S. Nestin+ cells direct inflammatory cell migration in atherosclerosis. *Nat Commun* (In press)
- 125 Nus M, Martínez-Poveda B; MacGrogan D; Chevre R; D'Amato G; Sbroglio M; Rodríguez C; Martínez-González J; **Andrés V**; Hidalgo A, de la Pompa J L. Endothelial Jag1-RBPJ signalling promotes inflammatory leukocyte recruitment and atherosclerosis. *Cardiovasc Res* (In press)
- 126 The CNIC. A Successful Vision in Cardiovascular Research. Fuster V, Ibáñez B, **Andrés V**. *Circ. Res*. 2016;119:785-789
127. Rivera-Torres J, J. Calvo C, Llach A, Guzmán-Martínez G, Caballero R, González-Gómez C, J. Jiménez-Borreguero L, A. Guadix J, G. Osorio F, López-Otín C, Herraiz-Martínez A, Cabello N, Vallmitjana A, Benítez R, B. Gordon L, Jalife J, M^a Pérez-Pomares J, Tamargo J, Delpón E, Hove-Madsen L, Filgueiras-Rama D, Andrés V. **Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations**. *Proc Nat. Acad Sci. USA* (In press)

BOOKS AND BOOK CHAPTERS

1. **Andrés, V**. Regulation of muscle phosphofructokinase by glucose 1,6-bisphosphate and fructose 2,6 biphosphate. Department of Biochemistry, School, of Medicine, University of Barcelona. Supervisor: Dr. Roser Cussó i Fresquet (1989) (**Doctoral Thesis**).
2. **Andrés, V**. Ciclo celular y arteriosclerosis inducida por la dieta. In: **Monografía XVIII. Mecanismos moleculares y neuroendocrinos del balance energético: Patologías**. Editor: Pascual-Leone, AM. (ISBN: 84-932423-9-X). Publisher: Instituto de España. Real Academia Nacional de Farmacia. Pages: 295-311 (2005) (**Book chapter**).
3. González-Navarro, H, Vila-Caballer, MA, **Andrés, V**. Modelos experimentales: Lecciones para el clínico. In: **Actualidad en la atención al climaterio y menopausia**. Editors: Vázquez, F, Palacios, S. (ISBN: 84-7592-829-3). Publisher: Ediciones Doyma, S. L. Pages: 45-47. (2006) (**Book chapter**).
4. **Andrés, V**, Wessely, R. Stent restenosis. In: **Encyclopedia of Molecular Mechanisms of Disease**. Editor: Lang, F. Publisher: Springer-Verlag (ISBN: 978-3-540-67136-7). Vol. 3, pages: 1985-1987. (2009) (**Book chapter**).
5. Gabriel, R, Pallardo, LF, Sendón, JL, González-Navarro, H, **Andrés, V**. Insulin resistance, cardio-metabolic syndrome and cardiovascular disease: Epidemiological, clinical and molecular links. In: **New Frontiers in Cardiovascular Research**, pages:.. Editors: Andrés, V, Fernández-Avilés, F, García-Dorado, D. Publisher: Research Signpost (ISBN: 978-81-308-0407-1). Pages: 31-63 (2010) (**Book chapter**).

6. Cruz González, I, Martín Moreiras, J, Sanz, R, **Andrés, V**, Sánchez, PL. Drug-eluting stents for coronary revascularization. In: ***New Frontiers in Cardiovascular Research***, pages: 219-249. Editors: Andrés, V, Fernández-Avilés, F, García-Dorado, D. Publisher: Research Signpost (ISBN: 978-81-308-0407-1) (2010) (**Book chapter**).
7. Fuster, JJ, Castillo, AI, Zaragoza, C, Ibáñez, B, **Andrés, V**. Animal models of atherosclerosis. In: ***Progress in Molecular Biology and Translational Science***, vol. 105 (Animal models of molecular pathology). Editor: Conn, P.M. Publisher: Academic Press – Elsevier (ISBN: 978-0-12-394596-9). Pages: 1-23 (2012) (**Book chapter**).
8. **Andrés, V**, Fuster, JJ, Silvestre, C, Wessely, R. Modulating the proliferative response to treat restenosis after vascular injury. In: ***Molecular and Translational Vascular Medicine***. Editors: Homeister, JW, Willis, MS. Publisher: Humana Press – Springer (ISBN: 978-1-61779-905-1). Pages: 227-248 (2012) (**Book chapter**).
9. Hamczyk, MR, Villa-Bellosta, R, **Andrés, V**. In vitro macrophage phagocytosis assay. In: ***Methods in Mouse Atherosclerosis*** (Methods in Molecular Biology Series). Editors: Andrés, V, Dorado, B. Publisher: Springer (ISBN: 978-1-4939-2928-3). Pages: 235-246 (2015) (**Book chapter**).
10. Molina-Sánchez, P., **Andrés, V**. Isolation of mouse primary aortic endothelial cells by selection with specific antibodies. In: ***Methods in Mouse Atherosclerosis*** (Methods in Molecular Biology Series). Editors: Andrés, V, Dorado, B. Publisher: Springer (ISBN: 978-1-4939-2928-3). Pages: 111-117 (2015) (**Book chapter**).
11. Andrés-Manzano, MJ., **Andrés, V.**, Dorado, B. Oil red O and hematoxylin and eosin staining for quantification of atherosclerosis burden in mouse aorta and aortic root. In: ***Methods in Mouse Atherosclerosis*** (Methods in Molecular Biology Series). Editors: Andrés, V, Dorado, B. Publisher: Springer (ISBN: 978-1-4939-2928-3). Pages: 85-99 (2015) (**Book chapter**).
12. **Andrés, V.**, Dorado, B., Spyridopoulos, I. Telomeres and cardiovascular disease: Facts, controversies and limitations. In: ***Intracellular cross pathways between aging, diseases and age estimation***. Editor: Casado-Zapico, S. Publisher: CRC Press (ISBN: in process). Pages: XX-XX (2016) (**Book chapter**).

BOOKS EDITED

1. ***New Frontiers in Cardiovascular Research*** (Editors: **Andrés, V**, Fernández-Avilés, F, García-Dorado, D.). Publisher: Research Signpost (ISBN: 978-81-308-0407-1) (2010).
2. ***Methods in Mouse Atherosclerosis*** (Methods in Molecular Biology Series). Editors: Andrés, V, Dorado, B. Publisher: Springer (ISBN: 978-1-4939-2928-3) (2015).

NON-PRINT PUBLICATIONS

1. Genebank Submission X69017; Canis sp. mRNA for Clox.
2. **Andrés, V.**, Wessely, R. In-stent restenosis: Molecular mechanisms and therapeutic principles. In: http://www.scitopics.com/In_stent_restenosis_Molecular_mechanisms_and_therapeutic_principles.html. SciTopics page (Elsevier).

PATENTS AND UTILITY MODELS

Title: Genetic markers of the risk of developing restenosis

Inventors: **Andrés, V.**, Silvestre, C., Fernández, P., Sánchez, P.L., Fernández-Avilés, F., Chaves, F.J.

Patent No: 200900507

Priority Country: Spain

Priority Date: 24-02-2009

Grant Date: 24-06-2011 (Spanish patent)

Holder Entity: Fina Biotech, S.L.U

Other countries to which the patent has been extended:

- Granted: US Patent Office (US 12/392,054)
- Application in progress: European Patent Office (10745851), Canada (CA2753460), China (201080008895), India (3287/KOLNP/2011), Japan (2011-550613)

Title: Optic device and Method for Detecting Cardiovascular Disease.

Inventors: Tobías Ackerman, Xabier Muñoz Berbel, Andreu Llobera Adán, Vicente Andrés García, Beatriz Julia Dorado de la Corte, Cristina Rius Leiva.

Patent No: 62156598 (Application Number) - US/641.1094 (Reference number) (US Patent Office)

Priority Country: USA

Priority Date: Submitted 4/05/2015

Grant Date:

Holder Entity:

Title: Biophotonic device and methods of use

Inventors: Ackerman, T., Muñoz, AX., Llobera, A., Rodríguez-Ruiz, I., Álvarez, ME., Andrés, V., Dorado, B., Rius, C., Simonsen, U., Röge, ME., Schou, MH.

Patent No: EP15382607.8 (Application Number) (Spanish Patent Office)

Priority Country: Spain

Priority Date: Submitted 4/12/2015

Grant Date:

Holder Entity:

STAYS IN INTERNATIONALLY RECOGNIZED CENTRES

- 1990 Department of Biochemistry, Boston University School of Medicine, Boston, US. Topic: Regulation of glycolytic flow oscillations in skeletal muscle (Short stay during doctoral thesis).
- 1991-1994 Department of Cardiology, Children's Hospital, Harvard University, Boston, US. Topic: Cloning and characterization of transcription factors of the homeobox and MEF2 families (Postdoctoral stay).
- 1994-1998 Division of Cardiovascular Research, St. Elizabeth's Medical Center, Tufts University, Boston, US. Topic: Transcriptional regulation and cell cycle control in cardiovascular disease (Research Investigator and Assistant Professor).

SUPERVISION OF PHD THESES

Completed PhD Theses

- 2003 Antonio Díez Juan. Title: Role of p27 in proliferation control and migration of vascular cells: Implications in cardiovascular physiopathology. University of Valencia. Mark: Outstanding “with honours” and Extraordinary Award (Supervisor: V. Andrés)
- 2004 Claudia M. Castro de Morcos. Title: Regulation of expression of p27 cellular cycle inhibitor in vascular smooth muscle myocytes: Therapeutic implications for cardiovascular pathologies treatment. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2005 Carmen Ivorra Ivorra. Title: Identification and characterization of interactions between AP-1 proto-oncogenes and nuclear lamin proteins. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2006 Silvia M. Sanz González. Title: Control of cellular cycle and vascular physiopathology: Role of p27^{Kip1} and p53 suppressors of cellular growth. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2006 María Dolores Edo Solsona. Title: Molecular and functional characterization of a new interaction between p27 cellular cycle inhibitor and SNX6, a protein involved in intracellular trafficking. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2010 María Amparo Vila Caballer. Title: Implication of CCL1 chemokine in atherosclerosis: Studies with cellular model and genetically-modified mice. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2010 Davinia Pla Ferrer. Title: Identification and functional characterization of the interaction between the proto-oncogen c-Fos and the centrosomal protein CEP2/C-NAP1. University of Valencia. Mark: Outstanding “with honours” (Supervisors: V. Andrés, José M. González)
- 2010 José Javier Fuster Ortuño. Title: Endolysosomal degradation of p27^{Kip1} mediated by SNX6 and role of p27^{Kip1} phosphorylation in atherosclerosis development. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2013 Carlos Silvestre Roig. Title: Identification of novel genetic markers and molecular mechanisms of restenosis following revascularization via angioplasty: Role of the transcription factor NF- κ B. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2013 Ángela Vinué Visús. Title: Role of the Ink4/Arf locus and insulin receptor substrate 2 (IRS2) in arteriosclerosis. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)
- 2015 Pedro Molina Sánchez. Title: Role of p27 phosphorylation at serine 10 in endothelial function and pathologic vascular remodeling. University of Valencia. Mark: Outstanding “with honours” (Supervisor: V. Andrés)

Ongoing PhD Theses

- 2011 Magda Rita Hamczyk. Title: Molecular and cellular mechanisms of cardiovascular disease in progeria. Autonomous University of Madrid (Supervisors: V. Andrés, R. Villa-Bellosta)
- 2014 Víctor Fanjul. Title: Identification of specific and shared mechanisms involved in physiological and premature aging and associated disorders. Autonomous University of Madrid (Supervisors: V. Andrés, C. López-Otín)

- 2014 Alberto del Monte. Title: Role of A-type lamins in cardiovascular disease. Autonomous University of Madrid (Supervisors: V. Andrés, C. Rius)
- 2014 Amanda Sánchez. Title: Alterations in vascular tone and structure induced by progerin: Molecular mechanisms and therapeutic strategies. Autonomous University of Madrid (Supervisor: V. Andrés)

SUPERVISION OF UNIVERSITY DEGREE FINAL PROJECTS

- 2009 David Jovani Sales. Title: Role of the oncosuppressors p15^{Ink4b}, p16^{Ink4a} y p19^{Arf} in high-fat diet induced atherosclerosis in the apolipoprotein E-null mouse model. Universidad Politécnica de Valencia. Mark: 10/10 points (Graduated with honors)
- 2011 Silvia González Ramos. Title: Role of p19^{Arf} gene in diabetes associated with hypercholesterolemia. Universidad Politécnica de Valencia. Mark: Outstanding
- 2012 Alba de Juan Guillén. Title: Analysis of the expression and function of the proto-oncogen c-Myc in tumor-associated macrophages. Autonomous University of Madrid. Mark: Outstanding
- 2015 Dunia Asensio Cob. Title: Evaluación del proceso de autofagia en el síndrome progerico HGPS. Universidad de Alcalá de Henares. Mark: 9.7/10 points
- 2016 Beatriz Carrascal Sanz. Title: "Papel de la lamina A/C en respuesta inmune innata en colitis inducida por DSS". Universidad Politécnica de Madrid. Mark: 8.7/10 points

SUPERVISION OF MASTERS COURSE FINAL PROJECTS

- 2009 Pedro Molina Sánchez. Title: Characterization of the role of the Ink4/Arf locus on atherosclerosis development in apolipoprotein E-deficient mice. University of Valencia. Mark: 8/10 points
- 2010 M^a Ángela Vinué Visús. Title: Molecular mechanisms of atherosclerosis in metabolic syndrome: Role of diminished insulin receptor substrate 2-dependent signaling. University of Valencia. Mark: Outstanding
- 2010 Ana Navarro Puche. Title: Rapid regulation of AP-1 transcriptional activity through the interaction between lamin A/C, ERK1/2 and c-FOS at the nuclear envelope. University of Valencia. Mark: Outstanding
- 2011 Irene Andrés Blasco. Title: Role of the INK4/ARF locus in diabetes development in mice deficient for p19^{ARF}. Universidad Politécnica de Valencia. Mark: Outstanding
- 2013 Alberto del Monte Monge. Title: Role of A-type lamins in the immune system. University of Alcalá. Mark: Outstanding
- 2014 Víctor Fanjul Hevia. Title: Proteomic alterations in normal and premature aging. University of Oviedo. Mark: 9,6/10 points.

SUPERVISION OF STUDENTS IN INTERNATIONAL PROGRAMMES

- 2010 Immacolata Longobardo. Erasmus student exchange programme
- 2010 Stefania Di Costanzo. Erasmus student exchange programme
- 2011 Vincenzo Giacco. Erasmus student exchange programme
- 2011 María Flavia Starita. Erasmus student exchange programme
- 2012 Sara Laudato. Erasmus student exchange programme
- 2012 Luisa Cirillo. Erasmus student exchange programme

- 2012 Angela Serena Maione. Erasmus student exchange programme
- 2012 Rosa D'Alessio. Erasmus student exchange programme
- 2013 Paola Brandi. Erasmus student exchange programme
- 2013 Veronica Bignoni. Erasmus student exchange programme
- 2014 Raffaella Fontanella. Erasmus student exchange programme
- 2014 Lucia de Stefano. Erasmus student exchange programme
- 2014 Gaetanina Golino. Erasmus student exchange programme
- 2015 Claudia Gucciardi. Erasmus student exchange programme
- 2015 Immacolata Giordano. Erasmus student exchange programme
- 2015 Giovanna Granata. Erasmus student exchange programme
- 2016 Simona Caleprico. Erasmus student exchange programme

OTHER TUTORING ACTIVITIES

- 2011 Magda Rita Hamczyk. CICERONE Teaching Programme. CNIC
- 2012 Víctor Fanjul Hevia. CICERONE Teaching Programme. CNIC
- 2013 Luis González Torres. INVESMIR Teaching Programme. CNIC
- 2013 Víctor Fanjul Hevia. CICERONE Teaching Programme. CNIC
- 2014 Jesús Victorino Santos. CICERONE Teaching Programme. CNIC
- 2015 Pablo Martínez Vives. RES@CNIC Teaching Programme. CNIC
- 2015 M^a Carmen Ortuño Costela. CICERONE Teaching Programme. CNIC
- 2016 Alejandro Travieso. RES@CNIC Teaching Programme. CNIC

SUPERVISION OF POSTDOCS

- 1997-1998 Alain Rivard, MD
- 1997-1998 Donghui Chen, MD
- 1997-1999 David Goukassian, MD, PhD
- 1998-1999 María J. Cortés Mateos, PhD
- 1999-2000 Ignacio Pérez Roger, PhD
- 2003 Antonio Serrano Sánchez, PhD
- 2003-2005 Markus Kubicek, PhD
- 2004-2005 Claudia Castro de Morcos, PhD
- 2005-2010 Herminia González Navarro, PhD
- 2006-2007 Silvia M. Sanz González, PhD
- 2007-2010 Yafa Naim Abu Nabah, PhD
- 2008-2011 Patricia Fernández Ferri, PhD
- 2009-2012 Laia Trigueros Motos, PhD
- 2010-2011 José Javier Fuster Ortuño, PhD
- 2010-2013 Oscar Muñoz Pello, PhD
- 2010-2013 Raphaël Chèvre, PhD
- 2012 Vanesa Esteban Vázquez, PhD
- 2005-present Jose M. González Granado, PhD
- 2009-2015 José Rivera Torres, PhD
- 2011- 2014 Ricardo Villa Bellosta, PhD

2013-present Cristina Rius Leiva, PhD
2013-present Lara del Campo Milán, PhD
2015-present Álvaro Macías Martínez

SUPERVISION OF LABORATORY TECHNICIANS

1995-1996 Gedeon Laura Wei
1997-1998 Amy Sylvester
1999-2000 Rosa Arroyo Pellicer
2001-2003 Paz Carbonell Rodríguez
2005-2009 Ana Navarro Puche
2006-2009 Ángela Vinué Visús
2007-2010 Rosa Viana Ballester
2012-2013 Alba de Juan Guillén
2009-present M^a Jesús Andrés Manzano
2010-present Cristina González Gómez

Laboratory Managers

2013-present Beatriz Julia Dorado de la Corte

ORGANIZATION OF R+D ACTIVITIES

- 2001 Co-organizer, Symposium “Frontiers in Molecular Pathology, XXIV Meeting of the Spanish Society of Biochemistry and Molecular Biology, Valencia, Spain
- 2004 Participant in the workshop to prepare the congress “Young scientists in cardiovascular disease research” given by Dr. T. Eschenhagen in the scientific sessions “The future of cardiovascular research in Europe”. Organized by the European Commission (Research Directorate – General, Major Diseases, Brussels)
- 2004 Director, Training Course “Current challenges in basic, clinical and epidemiological research in cardiovascular research”, Valencia, Spain. Organized by the Cardiovascular Disease Research Network (RECAVA), Institute of Health Carlos III (Instituto de Salud Carlos III), Spanish Ministry of Health
- 2005 Co-organizer, Symposium “Molecular Pathology, XXVIII Meeting of the Spanish Society of Biochemistry and Molecular Biology, Zaragoza, Spain
- 2005 Chairman, Training Course “Advances in cardiovascular research: Methodological, molecular, clinic and therapeutic aspects”. Cardiovascular Disease Research Network (RECAVA), Institute of Health Carlos III (Instituto de Salud Carlos III), Spanish Ministry of Health. Valencia, Spain
- 2007 Chairman, Session: “Vascular effects of vitamin D and analogues”, International Meeting on Vitamin D Receptors and Activation, Spanish Society of Nephrology. Barcelona, Spain
- 2007 Chairman, Cardiovascular Seminar: “Antagonizing Aging: Senescence and Telomerase Activity”, American Heart Association Scientific Sessions 2007, Orlando, USA
- 2009 Co-organizer, “First Annual Meeting of the Research Topic: Metabolic syndrome and cardiovascular risk”, Madrid, Spain (28-September-2009), Cardiovascular Disease Research Network (RECAVA), Institute of Health Carlos III (Instituto de Salud Carlos III), Spanish Ministry of Health
- 2009 Chairman, Session: Emerging molecular pathways in atherosclerosis, Training Course on Translational Cardiovascular Research, Cardiovascular Disease Research Network (RECAVA), Institute of Health Carlos III (Instituto de Salud Carlos III), Spanish Ministry of Health. Madrid, Spain
- 2010 Co-organizer, Workshop “New insights into cell & tissue interactions in cardiovascular development and disease”, Madrid. Organized by the Spanish National Center for Cardiovascular Research (CNIC)
- 2011 Chairman, Session: Vascular response to stent, Training Course “Atherothrombosis, thrombosis and vascular permeability”, Foundation Jiménez Díaz, Madrid, Spain
- 2012 Co-organizer, CNIC Conference 2012 “Vascular Inflammation, aging and imaging”, Madrid. Organized by the Spanish National Center for Cardiovascular Research (CNIC)
- 2013 Co-organizer, Symposium “Vascular wall, endothelium and platelets”, Sevilla, Spain, Annual Meeting of Spanish Society of Thrombosis and Haemostasia
- 2013 Chairman, Symposium “Vascular wall, endothelium and platelets”, Annual Meeting of the Spanish Society of Thrombosis and Haemostasia and the Spanish Society of Hematology and Hemotherapy, Sevilla, Spain
- 2013 Chairman, Session 2 “Cell cycle and cell division”, XV Meeting of the Spanish Society for Cell Biology, Madrid, Spain

- 2014 Chairman, Session: Advances in Cardiovascular Research, Training Course on Translational Research, Cardiovascular Research Network (RiC), Institute of Health Carlos III (Instituto de Salud Carlos III), Spanish Ministry of Economy and Competitiveness, Madrid, Spain
- 2015 Co-organizer Workshop "The nuclear lamina in health and disease", 2015 Programme "Current Trends in Biomedicine", Universidad Internacional de Andalucía, Baeza, Spain
- 2015 Co-organizer 2nd Course SEA-RIC Training Course on Translational Research: "Pathological Cardiovascular Remodeling: Molecular and clinical aspects", Instituto de Salud Carlos III, Madrid, Spain
- 2016 Co-organizer The Progeria Research Foundation 8th International Scientific Workshop, The Progeria Research Foundation, Boston, USA

DISEMINATION SEMINARS

1. CXLVI Conferencia de divulgación científica: "Retos de la Investigación y Medicina Cardiovascular". Colegio Infantil Paseo Rosales. Molina de Aragón, Murcia. 21 de abril de 2016.
2. CXLVII Conferencia de divulgación científica: "Retos de la Investigación y Medicina Cardiovascular". Fundación de Estudios Médicos de Molina de Segura. Murcia. 22 de abril de 2016.

LECTURES IN SCIENTIFIC MEETINGS

1996

Gene Therapy: Future Perspectives in Cardiovascular Disease. International Meeting "Cardiologia a Napoli 1996". Italian Society of Cardiology, Naples, Italy.

1999

Perspectives in the treatment of cardiovascular disease. 20th Course on Nephrology. Puigvert Foundation, Institute for Urology, Nephrology and Andrology, Santa Cruz y San Pablo Hospital, Autonomous University of Barcelona, Spain.

2001

Vascular remodeling and smooth muscle cell growth control: Physiopathological implications. VIII International Symposium of Reina Sofia Institute for Nephrological Research. Clinic Hospital, Barcelona, Spain.

Cell cycle control and atherosclerosis. "Frontiers in Molecular Pathology" Symposium. XXIV Congress of the Spanish Society of Biochemistry and Molecular Biology. University of Valencia, Spain.

2002

Molecular mechanisms of restenosis and atherosclerosis. International Menarini Foundation Symposium "Current concepts in myocardial ischemia and vascular diseases". Naples, Italy.

Cardiovascular disease: realities, necessities and expectations. "Vive la Ciencia" Conferences (CSIC-BBVA Foundation), Madrid, Spain.

Cell cycle control and cardiovascular pathology. II Symposium on Proliferation Control and Cellular Differentiation. A Biomedical Outlook (Ramón Areces Foundation). Murcia, Spain.

Cardiovascular disease: realities, necessities and expectations. “Vive la Ciencia” Conferences (CSIC-BBVA Foundation). Barcelona, Spain.

Role of p27 during vascular remodeling. II Conference on Angiogenesis. Veterinary Sciences Faculty, Autonomous University of Barcelona, Spain.

2003

Vascular role of telomerase and cell cycle genes. Third International Meeting on Myocardial Ischemia: From Molecular Adaptation to Cellular Repair. Capri, Italy.

Cardiovascular disease: realities, necessities and expectations. “Vive la Ciencia” Conferences (CSIC-BBVA Foundation). Córdoba, Spain.

2004

Mechanisms of anti-atherogenic effects of immunosuppressors. Fourth Wyeth International Transplantation Symposium. Sevilla, Spain.

Ageing, telomeres and atherosclerosis. Workshop “Mechanisms of organ specific ageing” (Research Directorate-General, European Commission). Brussels, Belgium.

How to fight cardiovascular disease. “Vive la Ciencia” Conferences (CSIC-BBVA Foundation). Madrid, Spain.

Molecular mechanisms of diet-induced atherosclerosis. Course “Energetic Balance and Neuroendocrine Control: Nutrition and Pathological Impacts”. Valencian Foundation for Advanced Studies, Valencia, Spain.

Atheroprotective mechanisms of rapamycin. Monographic Meeting on Sirolimus (organized by Wyeth). University Hospital La Fe, Valencia, Spain.

Experimental models of atherosclerosis and restenosis: Molecular and therapeutic aspects. Course “Current Challenges in Cardiovascular Research: Methodological, Molecular, Clinical, and Therapeutic Aspects”. Cardiovascular Disease Network, Institute of Health Carlos III (Instituto de Salud Carlos III), Valencia, Spain.

Cell cycle, telomere length and atherosclerosis. Group Meeting “Molecular Bases of Pathology”. XXVII Congress of the Spanish Society of Biochemistry and Molecular Biology. Lérida, Spain.

Proteomics for the identification of novel biomarkers and therapeutic targets in cardiovascular disease. II Meeting of the Valencian Genomics and Proteomics Network. Valencia, Spain.

How to fight cardiovascular disease. “Vive la Ciencia” Conferences (CSIC-BBVA Foundation). Valencia, Spain.

2005

Atheromatous lesion: Advances in physiopathology. 2nd International Course, Research Programme on Cardiovascular Disease Risk Factors. University of Talca, Talca, Chile.

Is telomere shortening a determinant or surrogate marker of cardiovascular disease? Workshop “Aging in Europe: From epidemiology to prevention and antiageing treatment”. Wroclaw, Poland.

Atherosclerosis and cardiovascular disease. Lessons from animal models. International Symposium of the Reina Sofía Institute for Nephrological Research. Alcalá de Henares, Spain.

2006

Telomeres, ageing and cardiovascular disease. International Symposium "Impact of age on the neuroendocrine and cardiovascular systems" (Ramón Areces Foundation). Murcia, Spain.

Age and atherosclerosis– which lessons have we learned? World Congress of Cardiology 2006 (European Society of Cardiology, World Heart Foundation). Barcelona, Spain.

Experimental models: lessons for the clinician. 6th Scientific Session: Cardiovascular system and sexual steroids. IX National Meeting of the Spanish Association for the Study of Menopause, Santiago de Compostela, Spain.

2007

Telomeres and cardiovascular disease. Sixth International Workshop on Structure and Function of the Vascular System. Paris, France.

Animal models of atherogenesis to search for immunosuppressors and antioxidants. 4th International Course, Research Programme on Cardiovascular Disease Risk Factors. University of Talca, Talca, Chile.

Role of proliferation signal inhibitors (PSI) in transplanted patients with atherosclerosis. 2nd Forum on PSI. Novartis Pharmaceuticals. Madrid, Spain.

Cell cycle control and neointimal lesion development: from the animal model to the patient. VII Scientific Meeting of the Experimental Cardiology Working Group (Spanish Society of Cardiology). Valencia, Spain.

2008

Murine models to investigate cardiovascular diseases. International Symposium "Signalling Networks and Inflammatory Pathologies". Madrid, Spain.

Potential role of mTOR inhibitors on arteriosclerosis and cancer. Scientific Session, Nephrology Service, La Fe University Hospital. Valencia, Spain.

Cell cycle, arteriosclerosis and restenosis post-angioplasty. III Conference on Biomedical Research Updates. Organized by the Valencian Foundation for Advanced Studies, Peset Hospital Research Foundation. Valencia, Spain.

Cell cycle, atherosclerosis and restenosis: Basic and clinical aspects. 2008 Vascular Biology and Inflammation Retreat, CNIC. Sigüenza, Spain.

Molecular mechanisms of atherosclerosis in metabolic syndrome: Role of reduced IRS-2-dependent signalling. Annual Meeting, Network of Cooperative Cardiovascular Research (RECAVA). Spanish National School of Health, Madrid, Spain.

2009

Rapid regulation of AP-1 transcription factor activity through interaction of A-type lamins, ERK1/2 and c-Fos at the nuclear envelope. EMBO Workshop "The multiple faces of lamins in aging and disease". Vienna, Austria.

Telomere biology, A-type lamins and cardiovascular disease. Heart Failure Research Winter Meeting 2009. Heart Failure Association, European Society of Cardiology. Les Diablerets, Switzerland.

Telomere biology and cardiovascular disease. American Heart Association Scientific Sessions 2009. Cardiovascular Seminar on "Epigenetic Control of Cardiovascular Disease". Orlando, Florida, US.

Phosphorylation of the growth suppressor p27 in serine 10 protects from arteriosclerosis development. Symposium “Advances in the pathophysiology of atherosclerosis”. XXII Meeting of the Spanish Society of Arteriosclerosis. Pamplona, Spain.

Careers in Basic Research. 3rd CICERONE Conferende (Training Programme CNIC-JOVEN). Barcelona, Spain.

Cell cycle regulation and atherosclerosis. Meeting on Translational Research CNIC. Madrid, Spain.

Cell cycle and atherosclerosis: Molecular mechanisms and clinical applications. Training Course on Translational Cardiovascular Research, Organized by the Cardiovascular Disease Research Network (RECAVA). Madrid, Spain.

2010

Role of cell cycle genes in the development of occlusive vascular lesions: a round trip from bench to bedside. 29th Annual Scientific Meeting, Belgian Society of Cardiology. Brussels, Belgium.

Role of the tumor suppressor p27 in renal and cardiovascular disease. VII International Conference “Hypertension and Kidney”. Madrid, Spain.

Tumour suppressor genes and cardiovascular disease. 16th World Congress of Basic and Clinical Pharmacology (WorldPharma 2010). Copenhagen, Denmark.

New genetic and molecular mechanisms of aging and cardiovascular disease. CNIC Applied Departments Retreat. Madrid, Spain.

Cardiovascular remodeling: a HERACLES-RECAVA meeting point. Annual meeting of the HERACLES Network. Granada, Spain.

2011

Telomeres, tumor suppressors and cardiovascular disease. Berzelius Symposium on “Telomere biology in health and disease – a cristal ball for the future?” Stockholm, Sweden.

Role of tumor suppressor genes in atherosclerosis: Animal models and clinical implications. 4th Meeting of Research in Vascular Pathophysiology. Spanish Society of Hypertension, Barcelona, Spain.

The role of the transcription factor NF- κ B in arteriosclerosis y restenosis. IX Scientific Meeting of the Experimental Cardiology Work Group. Madrid, Spain.

The transcription factor NF- κ B is activated during atherosclerosis and restenosis post-stent and is essential for PDGF-BB-induced mitogenesis in vascular smooth muscle cells. Annual Meeting of the Thrombosis Group. Spanish Society of Cardiology, Murcia, Spain.

Molecular basis of atherosclerosis and restenosis post-PTCA. Course of Cardiovascular Physiology and Pathophysiology “From the symptom to the genes”, Spanish Society of Cardiology-CNIC. Madrid, Spain.

2012

An integrated approach to identify novel mechanisms underlying progeria and associated cardiovascular disease: Basic and translational aspects. New Frontiers in Progeria Research, The Progeria Research Foundation Research Meeting. Boston, US.

20th Anniversary Session. XX Workshop “Advances in Molecular Biology for Young Researchers Abroad”. Spanish National Center for Biotechnology, Spain.

2013

Cardiovascular disease in progeria and normal aging. 2013 Progeria Research Foundation Workshop on Progeria. Washington DC, US.

Cardiovascular disease in normal and premature aging. Symposium “Aging as cardiovascular risk factor”, Programme “Excellence Interdisciplinary Research on Healthy Ageing”. University of Talca, Talca, Chile.

Molecular and genetic mechanisms of restenosis post-angioplasty. XXVI National Meeting Spanish Society of Arteriosclerosis. Zaragoza, Spain.

Mechanisms of cardiovascular disease induced by progerin: New connections between premature and physiological aging. Annual Meeting Spanish Society Thrombosis and Haemostasia and Spanish Society of Hematology and Hemotherapy. Sevilla, Spain.

Understanding the roles of nuclear A-type lamins in aging and disease. XV Meeting Spanish Society of Cell Biology. Madrid, Spain.

Molecular and genetic basis of restenosis post-angioplasty. Course of Cardiovascular Pathophysiology “From the symptom to the genes”. Spanish Society of Cardiology-CNIC. Madrid, Spain.

2014

New roles of macrophages in cardiovascular disease and aging. 3rd Madrid Meeting on Dendritic Cells and Macrophages. Spanish National Center for Biotechnology. Madrid, Spain.

2015

Cardiovascular disease in LMNA-related premature ageing syndromes, XII Congress of Mediterranean Society of Myology, Naples (Italy)

Regulation of aging and cardiovascular disease by A-type lamins, Gordon Research Conference on “Genome Architecture in Cell Fate and Disease”, Hong Kong, China

Role of A-type lamins in aging and cardiovascular disease (Keynote lecture). XXXI LIAC Meeting on Vascular Research: Lisbon, Portugal

The nuclear lamina and cardiovascular disease, Workshop “The nuclear lamina in health and disease”, 2015 Programme “Current Trends in Biomedicine”, Universidad Internacional de Andalucía, Baeza, Spain

The role of progerin in atherosclerosis development: animal and human findings and therapeutical implications. 13th Vulnerable Patient Meeting, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Lamin A/C, cardiovascular disease and aging, 2nd Course Residents, Training in Biomedical Research, Hospital Universitario La Paz, Madrid, Spain

The polypill project and beyond, Scientific Meeting CNIC, Madrid, Spain.

2016

New animal models to study Hutchinson-Gilford progeria syndrome, I Forum of Basic and Clinical Research in Diabetes, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain

The essential basics in progeria: Landmark preclinical research findings, The Progeria Research Foundation 8th International Scientific Workshop, The Progeria Research Foundation, Boston, USA

CNIC: Organization and Mission, 5th Symposium On Stroke, Cognitive Impairment and Neuropathy Management, CNIC, Madrid, Spain.

INVITED SEMINARS

1993

mClox: A new family of homeobox genes with a bipartite DNA-binding domain. Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio, US.

mClox: A new family of homeobox genes with a bipartite DNA-binding domain. Research and Development Center. CSIC, Barcelona, Spain.

Cut and mClox: A new family of homeoproteins with a bipartite DNA-binding domain. Department of Biochemistry and Physiology, University of Barcelona.

1994

Prevention and treatment of cardiovascular disease. American Heart Association. Massachusetts Affiliate, Framingham, Massachusetts, US.

Homeobox genes, MEF2 and transcriptional regulation during commitment and differentiation of muscle cells. Research and Development Center. CSIC, Barcelona, Spain.

1995

Temporal relationship between cell cycle withdrawal and myogenic differentiation. Cardiovascular Department, Berlex Biosciences, Richmond, California, US.

Interplay and temporal relationship between cell proliferation and myogenic differentiation. Department of Anatomy & Cell Biology, Tufts University School of Medicine, Boston, Massachusetts, US.

Cell cycle control and perspectives for the treatment and prevention of atherosclerosis and restenosis. Research and Development Center. CSIC, Barcelona, Spain.

1996

Control of vascular smooth muscle cell proliferation. IV Workshop "Advances in Molecular and Cellular Biology". National Center for Biotechnology, Spain.

Cell cycle control and perspectives for the treatment and prevention of atherosclerosis and restenosis. Department of Biochemistry and Molecular Biology, University of Barcelona.

Cell cycle control and perspectives for the treatment and prevention of cardiovascular disease. Cytological Research Institute, Valencia, Spain

1997

Control of smooth muscle cell proliferation during vascular remodeling after angioplasty. Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania, US.

1998

Cell cycle control and cardiovascular disease. Department of Physiology, Tufts University School of Medicine, Boston, Massachusetts, US.

1999

Cell cycle control in vascular smooth muscle and implications for the treatment of cardiovascular disease. Scientific Sessions. Health Sciences Department, University of Barcelona, Spain.

Cell cycle control in vascular smooth muscle: Implications for the treatment of cardiovascular disease. Department of Medical Physiology and Biophysics, School of Medicine, University of Sevilla, Spain.

Cell cycle control in smooth muscle: implications for the treatment of cardiovascular disease. “Alberto Sols” Institute for Biomedical Research. CSIC, Madrid, Spain.

2000

Molecular mechanisms of cardiovascular disease and therapeutic expectations. XI Course on “Advances in metabolic studies”. Bellvitge Campus, University of Barcelona, Spain.

Role of the cell cycle inhibitor p27 in vascular pathophysiology. Cytological Research Institute, Valencia, Spain.

Role of the cell cycle inhibitor p27 in cardiovascular pathophysiology. Service of Biochemistry-Research, Ramón y Cajal Hospital, Madrid, Spain.

Role of the cell cycle inhibitor p27 in the pathogenesis of cardiovascular disease. Department of Immunology and Oncology, Spanish National Center for Biotechnology. CSIC, Autonomous University of Madrid, Spain.

2001

Cell cycle and atherosclerosis. Week of Science and Technology (Ministry of Science and Technology). Biomedicine Institute of Valencia, Spain.

Role of the cell cycle inhibitor p27 in the pathogenesis of atherosclerosis. Basic Medical Sciences Department, Medicine Faculty, University of Lleida.

Role of the CDK inhibitor p27 in the pathogenesis of atherosclerosis. Cancer Research Center, University of Salamanca – CSIC. Salamanca, Spain.

2002

Control of vascular cell proliferation and migration: Implications in cardiovascular pathology. Institute for Oncological Research, Hospital Duran i Reynals, Barcelona, Spain.

Role of c-fos and p27 in cardiovascular pathology: Therapeutic implications. Institute for Biomedical Research, Parc Científic Barcelona, Barcelona, Spain

2004

Cell cycle control, microarray analysis and atherosclerosis: Lessons learned from induced murine models. Gulbekian Science Institute, Oeiras, Portugal.

Role of the growth suppressor in atheroma development. Clínico San Carlos Hospital, Madrid, Spain.

Cell cycle, telomeres and cardiovascular disease. CSIC, Biomedical Research Institute of Barcelona, Barcelona, Spain.

Cellular proliferation, telomere length and atherosclerosis. Center for Biological Research. CSIC, Madrid, Spain.

Animal models to elucidate molecular mechanisms of cardiovascular disease and identification of diagnostic markers. Department of Biochemistry Pharmacology, School of Medicine, Complutense University of Madrid, Spain.

Role of the growth suppressor p27 in restenosis and atherosclerosis. “Severo Ochoa” Molecular Biology, CSIC, Autonomous University of Madrid, Spain.

2005

What can we learn from genetically-modified mice about atheroma development? Scientific session on “Genetic manipulation in animals for the study of human diseases”. Animal Biotechnology and Gene therapy Center, Autonomous University of Barcelona, Spain.

Identification and characterization of the interaction between the protooncogen c-Fos and lamin A/C. University of Santiago de Compostela, Spain.

Role of the growth suppressor p27 on atherosclerotic plaque development. University of Castilla-La Mancha, Albacete, Spain.

Role of the growth suppressor p27 on restenosis and atherosclerosis. Municipal Institute of Medical Research, Barcelona, Spain.

Interaction between the proto-oncogen c-Fos and A-type lamins, a novel mechanism of AP-1 transcription factor regulation. Faculty of Biology, University of Barcelona, Spain.

Cell cycle control during vascular remodeling: from the experimental animal to clinical practice. Applied Medical Research Center, University of Navarra, Pamplona, Spain.

2006

A novel mechanism of AP-1 suppression trough interaction of c-Fos with A-type lamins. Spanish National Center for Cancer Research. Madrid, Spain.

Role of the growth suppressors p27 and p53 in experimental models of mechanical denudation and atherosclerosis: Therapeutic and diagnostic implications. Barcelona Clínico Hospital/IDIBAPS, Barcelona, Spain.

2007

Animal models of atherosclerosis. Faculty of Pharmacy, University of Concepción, Chile.

Regulation and functional consequences of the interaction between the c-Fos proto-oncogen and lamin A/C. Unit of Biomedicine, CSIC-University of Cantabria, Santander, Spain.

Role of the nuclear envelope on the regulation of gene transcription and cell cycle: interaction between the c-Fos proto-oncogene and lamin A/C. School of Medicine, University of Barcelona, Barcelona, Spain.

Functional consequences and regulation of the interaction between the proto-oncogen c-Fos and the nuclear envelop protein lamin A/C. Animal Biotechnology and Gene Therapy Center, Bellaterra, Barcelona, Spain.

2008

Cell cycle control and neointimal thickening: Molecular mechanisms and diagnostic opportunities. Department of Cardiology, Klinik an der Technischen Universität München, Munich, Germany.

Interaction between the proto-oncogene c-Fos and lamin A/C: Regulation and functional consequences. Basic Medical Sciences Department, Faculty of Medicine, University of Lleida, Spain.

Potential role of mTOR inhibitors on arteriosclerosis and tumors. Service of Nephrology, La Fe University Hospital, Valencia, Spain.

2009

p27, cell cycle and vascular obstructive disease. Basic Medical Sciences Department, Faculty of Medicine, University of Lleida, Spain.

Cell cycle control in the arterial wall: Molecular and genetic mechanisms and clinical implications. Service of Cardiology, Vall d'Hebron University Hospital, Barcelona, Spain.

2010

Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2 and c-Fos at the nuclear envelope. Andalusian Center for Development of Biology (Centro Andaluz de Biología del Desarrollo), Sevilla, Spain.

Role of A-type lamins in the regulation of signal transduction and gene transcription: Effects on ERK1/2 and c-Fos. Institute of Biology and Molecular Genetics, Valladolid, Spain.

2011

Role of p27 and NF-Y in atherosclerosis and restenosis: What have we learned from rodents and patients. Institute of Biomedicine of Seville (IBIS), Sevilla, Spain.

2012

Role of lamin A/C in aging and cardiovascular disease. School of Medicine, Complutense University of Madrid, Spain.

2013

A-type lamins, premature aging and cardiovascular disease: Genetic and molecular basis and translational approaches. Applied Medical Research Center, Pamplona, Spain.

2015

A-type lamins, progeria and cardiovascular disease, Instituto de Investigaciones Biomédicas (CSIC) – Facultad de Medicina, Universidad Autónoma de Madrid, Spain

2016

Role of A-type lamins in aging and cardiovascular disease, Instituto de Investigación en Enfermedades Raras-ISCIII, Majadahonda, Madrid

Role of nuclear A-type lamins in cardiovascular disease and aging, Whitaker Cardiovascular Institute, Boston University, Boston, USA